<?xml version="1.0" encoding="UTF-8"?><!-- Normalized for easier text mining. --><xocs:doc xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.elsevier.com/xml/ja/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://schema.elsevier.com/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>271023</xocs:cid><xocs:srctitle>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</xocs:srctitle><xocs:normalized-srctitle>BIOCHIMICAETBIOPHYSICAACTABBAMOLECULARBASISDISEASE</xocs:normalized-srctitle><xocs:orig-load-date>2013-04-18</xocs:orig-load-date><xocs:ew-transaction-id>2014-02-11T08:53:06</xocs:ew-transaction-id><xocs:eid>1-s2.0-S0925443913001385</xocs:eid><xocs:pii-formatted>S0925-4439(13)00138-5</xocs:pii-formatted><xocs:pii-unformatted>S0925443913001385</xocs:pii-unformatted><xocs:doi>10.1016/j.bbadis.2013.04.014</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.3</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S0925443913X00067</xocs:hub-eid><xocs:timestamp>2014-02-11T04:08:54.211093-05:00</xocs:timestamp><xocs:issns><xocs:issn-primary-formatted>0925-4439</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>09254439</xocs:issn-primary-unformatted></xocs:issns><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>WT</xocs:funding-body-id><xocs:crossmark>false</xocs:crossmark><xocs:vol-first>1832</xocs:vol-first><xocs:iss-first>8</xocs:iss-first><xocs:vol-iss-suppl-text>Volume 1832, Issue 8</xocs:vol-iss-suppl-text><xocs:sort-order>22</xocs:sort-order><xocs:first-fp>1304</xocs:first-fp><xocs:last-lp>1312</xocs:last-lp><xocs:pages><xocs:first-page>1304</xocs:first-page><xocs:last-page>1312</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>201308</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>August 2013</xocs:cover-date-text><xocs:cover-date-start>2013-08-01</xocs:cover-date-start><xocs:cover-date-end>2013-08-31</xocs:cover-date-end><xocs:cover-date-year>2013</xocs:cover-date-year><xocs:hub-sec><xocs:hub-sec-title>Regular papers</xocs:hub-sec-title></xocs:hub-sec><xocs:document-type>article</xocs:document-type><xocs:document-subtype>fla</xocs:document-subtype><xocs:copyright-line>Copyright Â© 2013 The Authors. Published by Elsevier B.V. All rights reserved.</xocs:copyright-line><xocs:normalized-article-title>MUTATIONSINMITOCHONDRIALRIBOSOMALPROTEINMRPL12LEADSGROWTHRETARDATIONNEUROLOGICALDETERIORATIONMITOCHONDRIALTRANSLATIONDEFICIENCY</xocs:normalized-article-title><xocs:normalized-first-auth-surname>SERRE</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>V</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>1</xocs:item-toc-label><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2</xocs:item-toc-label><xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.1</xocs:item-toc-label><xocs:item-toc-section-title>Analysis of oxidative phosphorylation activities</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.2</xocs:item-toc-label><xocs:item-toc-section-title>Microsatellite genotyping and mutation screening</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.3</xocs:item-toc-label><xocs:item-toc-section-title>Cell culture</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.4</xocs:item-toc-label><xocs:item-toc-section-title>Protein analysis</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5</xocs:item-toc-label><xocs:item-toc-section-title>Metabolic labelling of mitochondrial translation products</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.6</xocs:item-toc-label><xocs:item-toc-section-title>Homology modeling of the human MRPL12 protein</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.7</xocs:item-toc-label><xocs:item-toc-section-title>Cell lysates, Westerns and isokinetic sucrose gradients</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.8</xocs:item-toc-label><xocs:item-toc-section-title>RNA and Northern blotting</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3</xocs:item-toc-label><xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.1</xocs:item-toc-label><xocs:item-toc-section-title>Clinical report</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.2</xocs:item-toc-label><xocs:item-toc-section-title>Blue native-PAGE analysis</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.3</xocs:item-toc-label><xocs:item-toc-section-title>Identifying the causative mutation by Microsatellite genotyping and mutation screening</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.4</xocs:item-toc-label><xocs:item-toc-section-title>In silico analysis of the putative impact of A181V substitution</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.5</xocs:item-toc-label><xocs:item-toc-section-title>Ribosome assembly</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.6</xocs:item-toc-label><xocs:item-toc-section-title>In vitro translation</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.7</xocs:item-toc-label><xocs:item-toc-section-title>Steady-state level of mitochondrial transcripts</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.8</xocs:item-toc-label><xocs:item-toc-section-title>MRPL12 dimerization and interaction with the mitoribosome</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="rf0005"><xocs:ref-normalized-surname>ANDERSON</xocs:ref-normalized-surname><xocs:ref-pub-year>1981</xocs:ref-pub-year><xocs:ref-first-fp>457</xocs:ref-first-fp><xocs:ref-last-lp>465</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0010"><xocs:ref-normalized-surname>ZEVIANI</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>564</xocs:ref-first-fp><xocs:ref-last-lp>571</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0015"><xocs:ref-normalized-surname>KEMP</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>183</xocs:ref-first-fp><xocs:ref-last-lp>195</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0020"><xocs:ref-normalized-surname>CALVO</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>118ra110</xocs:ref-first-fp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0025"><xocs:ref-normalized-surname>GALMICHE</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1225</xocs:ref-first-fp><xocs:ref-last-lp>1231</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0030"><xocs:ref-normalized-surname>GREAVES</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>274</xocs:ref-first-fp><xocs:ref-last-lp>286</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0035"><xocs:ref-normalized-surname>BARTH</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>349</xocs:ref-first-fp><xocs:ref-last-lp>354</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0040"><xocs:ref-normalized-surname>VALIANPOUR</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>560</xocs:ref-first-fp><xocs:ref-last-lp>566</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0045"><xocs:ref-normalized-surname>YLIKALLIO</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>41</xocs:ref-first-fp><xocs:ref-last-lp>59</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0050"><xocs:ref-normalized-surname>CHRZANOWSKALIGHTOWLERS</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>142</xocs:ref-first-fp><xocs:ref-last-lp>147</xocs:ref-last-lp><xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0055"><xocs:ref-normalized-surname>MCFARLAND</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>210</xocs:ref-first-fp><xocs:ref-last-lp>228</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0060"><xocs:ref-normalized-surname>CHRISTIAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1035</xocs:ref-first-fp><xocs:ref-last-lp>1054</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0065"><xocs:ref-normalized-surname>YARHAM</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>304</xocs:ref-first-fp><xocs:ref-last-lp>324</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0070"><xocs:ref-normalized-surname>ROTIG</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1198</xocs:ref-first-fp><xocs:ref-last-lp>1205</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0075"><xocs:ref-normalized-surname>COENEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>2080</xocs:ref-first-fp><xocs:ref-last-lp>2086</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0080"><xocs:ref-normalized-surname>ANTONICKA</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>1835</xocs:ref-first-fp><xocs:ref-last-lp>1846</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0085"><xocs:ref-normalized-surname>SMEITINK</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>869</xocs:ref-first-fp><xocs:ref-last-lp>877</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0090"><xocs:ref-normalized-surname>VALENTE</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>44</xocs:ref-first-fp><xocs:ref-last-lp>58</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0095"><xocs:ref-normalized-surname>EDVARDSON</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>857</xocs:ref-first-fp><xocs:ref-last-lp>862</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0100"><xocs:ref-normalized-surname>SCHEPER</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>534</xocs:ref-first-fp><xocs:ref-last-lp>539</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0105"><xocs:ref-normalized-surname>RILEY</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>52</xocs:ref-first-fp><xocs:ref-last-lp>59</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0110"><xocs:ref-normalized-surname>BELOSTOTSKY</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>193</xocs:ref-first-fp><xocs:ref-last-lp>200</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0115"><xocs:ref-normalized-surname>PIERCE</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>6543</xocs:ref-first-fp><xocs:ref-last-lp>6548</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0120"><xocs:ref-normalized-surname>GOTZ</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>635</xocs:ref-first-fp><xocs:ref-last-lp>642</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0125"><xocs:ref-normalized-surname>BAYAT</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>e1001288</xocs:ref-first-fp><xocs:ref-normalized-initial>V</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0130"><xocs:ref-normalized-surname>STEENWEG</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>1387</xocs:ref-first-fp><xocs:ref-last-lp>1394</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0135"><xocs:ref-normalized-surname>ELO</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>4521</xocs:ref-first-fp><xocs:ref-last-lp>4529</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0140"><xocs:ref-normalized-surname>ZEHARIA</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>449</xocs:ref-first-fp><xocs:ref-last-lp>452</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0145"><xocs:ref-normalized-surname>ZEHARIA</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>401</xocs:ref-first-fp><xocs:ref-last-lp>407</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0150"><xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>27256</xocs:ref-first-fp><xocs:ref-last-lp>27264</xocs:ref-last-lp><xocs:ref-normalized-initial>X</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0155"><xocs:ref-normalized-surname>ANTONICKA</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>115</xocs:ref-first-fp><xocs:ref-last-lp>122</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0160"><xocs:ref-normalized-surname>WERAARPACHAI</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>833</xocs:ref-first-fp><xocs:ref-last-lp>837</xocs:ref-last-lp><xocs:ref-normalized-initial>W</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0165"><xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>331</xocs:ref-first-fp><xocs:ref-last-lp>336</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0170"><xocs:ref-normalized-surname>WERAARPACHAI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>142</xocs:ref-first-fp><xocs:ref-last-lp>151</xocs:ref-last-lp><xocs:ref-normalized-initial>W</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0175"><xocs:ref-normalized-surname>MILLER</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>734</xocs:ref-first-fp><xocs:ref-last-lp>738</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0180"><xocs:ref-normalized-surname>SAADA</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>784</xocs:ref-first-fp><xocs:ref-last-lp>786</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0185"><xocs:ref-normalized-surname>KOC</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>45</xocs:ref-first-fp><xocs:ref-last-lp>59</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0190"><xocs:ref-normalized-surname>OBRIEN</xocs:ref-normalized-surname><xocs:ref-pub-year>1990</xocs:ref-pub-year><xocs:ref-first-fp>174</xocs:ref-first-fp><xocs:ref-last-lp>178</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0195"><xocs:ref-normalized-surname>HELGSTRAND</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>468</xocs:ref-first-fp><xocs:ref-last-lp>479</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0200"><xocs:ref-normalized-surname>DEY</xocs:ref-normalized-surname><xocs:ref-pub-year>1995</xocs:ref-pub-year><xocs:ref-first-fp>925</xocs:ref-first-fp><xocs:ref-last-lp>930</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0205"><xocs:ref-normalized-surname>PETTERSSON</xocs:ref-normalized-surname><xocs:ref-pub-year>1980</xocs:ref-pub-year><xocs:ref-first-fp>4007</xocs:ref-first-fp><xocs:ref-last-lp>4010</xocs:ref-last-lp><xocs:ref-normalized-initial>I</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0210"><xocs:ref-normalized-surname>RUSTIN</xocs:ref-normalized-surname><xocs:ref-pub-year>1994</xocs:ref-pub-year><xocs:ref-first-fp>35</xocs:ref-first-fp><xocs:ref-last-lp>51</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0215"><xocs:ref-normalized-surname>CALVO</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>576</xocs:ref-first-fp><xocs:ref-last-lp>582</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0220"><xocs:ref-normalized-surname>VOGEL</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>7582</xocs:ref-first-fp><xocs:ref-last-lp>7590</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0225"><xocs:ref-normalized-surname>CHOMYN</xocs:ref-normalized-surname><xocs:ref-pub-year>1996</xocs:ref-pub-year><xocs:ref-first-fp>197</xocs:ref-first-fp><xocs:ref-last-lp>211</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0230"><xocs:ref-normalized-surname>SOLEIMANPOURLICHAEI</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>745</xocs:ref-first-fp><xocs:ref-last-lp>757</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0235"><xocs:ref-normalized-surname>RICHTER</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>1116</xocs:ref-first-fp><xocs:ref-last-lp>1125</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0240"><xocs:ref-normalized-surname>CHRZANOWSKALIGHTOWLERS</xocs:ref-normalized-surname><xocs:ref-pub-year>1994</xocs:ref-pub-year><xocs:ref-first-fp>27322</xocs:ref-first-fp><xocs:ref-last-lp>27328</xocs:ref-last-lp><xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0245"><xocs:ref-normalized-surname>NIJTMANS</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>327</xocs:ref-first-fp><xocs:ref-last-lp>334</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0250"><xocs:ref-normalized-surname>HEMMERICH</xocs:ref-normalized-surname><xocs:ref-pub-year>1993</xocs:ref-pub-year><xocs:ref-first-fp>223</xocs:ref-first-fp><xocs:ref-last-lp>231</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0255"><xocs:ref-normalized-surname>MOHR</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>12520</xocs:ref-first-fp><xocs:ref-last-lp>12528</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0260"><xocs:ref-normalized-surname>DIACONU</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>991</xocs:ref-first-fp><xocs:ref-last-lp>1004</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0265"><xocs:ref-normalized-surname>NECHIFOR</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>36998</xocs:ref-first-fp><xocs:ref-last-lp>37005</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0270"><xocs:ref-normalized-surname>KOPKE</xocs:ref-normalized-surname><xocs:ref-pub-year>1992</xocs:ref-pub-year><xocs:ref-first-fp>1382</xocs:ref-first-fp><xocs:ref-last-lp>1390</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0275"><xocs:ref-normalized-surname>GREGORET</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>119</xocs:ref-first-fp><xocs:ref-last-lp>126</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0280"><xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>12610</xocs:ref-first-fp><xocs:ref-last-lp>12618</xocs:ref-last-lp><xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0285"><xocs:ref-normalized-surname>SUROVTSEVA</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>17921</xocs:ref-first-fp><xocs:ref-last-lp>17926</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0310"><xocs:ref-normalized-surname>DENNERLEIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>551</xocs:ref-first-fp><xocs:ref-last-lp>558</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0290"><xocs:ref-normalized-surname>KOC</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>1055</xocs:ref-first-fp><xocs:ref-last-lp>1066</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0295"><xocs:ref-normalized-surname>BOCHAROV</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>347</xocs:ref-first-fp><xocs:ref-last-lp>350</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0300"><xocs:ref-normalized-surname>DEROO</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>1120</xocs:ref-first-fp><xocs:ref-last-lp>1127</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0305"><xocs:ref-normalized-surname>OLEINIKOV</xocs:ref-normalized-surname><xocs:ref-pub-year>1993</xocs:ref-pub-year><xocs:ref-first-fp>917</xocs:ref-first-fp><xocs:ref-last-lp>922</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info></xocs:references><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S0925-4439(13)00138-5</xocs:pii-formatted><xocs:pii-unformatted>S0925443913001385</xocs:pii-unformatted><xocs:eid>1-s2.0-S0925443913001385</xocs:eid><xocs:doi>10.1016/j.bbadis.2013.04.014</xocs:doi><xocs:cid>271023</xocs:cid><xocs:timestamp>2014-02-11T04:08:54.211093-05:00</xocs:timestamp><xocs:path>/271023/1-s2.0-S0925443913X00067/1-s2.0-S0925443913001385/</xocs:path><xocs:cover-date-start>2013-08-01</xocs:cover-date-start><xocs:cover-date-end>2013-08-31</xocs:cover-date-end><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>WT</xocs:funding-body-id><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S0925443913001385-main.pdf</xocs:attachment-eid><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>891031</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>9</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S0925443913001385-main_1.png</xocs:attachment-eid><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>138627</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr7_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>291106</xocs:filesize><xocs:pixel-height>1218</xocs:pixel-height><xocs:pixel-width>2243</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr6_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>291519</xocs:filesize><xocs:pixel-height>1897</xocs:pixel-height><xocs:pixel-width>1587</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr5_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>405628</xocs:filesize><xocs:pixel-height>2634</xocs:pixel-height><xocs:pixel-width>1678</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr4_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>244979</xocs:filesize><xocs:pixel-height>1334</xocs:pixel-height><xocs:pixel-width>2225</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr3_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>489033</xocs:filesize><xocs:pixel-height>1103</xocs:pixel-height><xocs:pixel-width>2211</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr2_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>1230846</xocs:filesize><xocs:pixel-height>3741</xocs:pixel-height><xocs:pixel-width>2269</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr1_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>213936</xocs:filesize><xocs:pixel-height>1873</xocs:pixel-height><xocs:pixel-width>1178</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr7.jpg</xocs:attachment-eid><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>32273</xocs:filesize><xocs:pixel-height>275</xocs:pixel-height><xocs:pixel-width>506</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr6.jpg</xocs:attachment-eid><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>26361</xocs:filesize><xocs:pixel-height>428</xocs:pixel-height><xocs:pixel-width>358</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr5.jpg</xocs:attachment-eid><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>44681</xocs:filesize><xocs:pixel-height>595</xocs:pixel-height><xocs:pixel-width>379</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr4.jpg</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>29274</xocs:filesize><xocs:pixel-height>301</xocs:pixel-height><xocs:pixel-width>502</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr3.jpg</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>40840</xocs:filesize><xocs:pixel-height>249</xocs:pixel-height><xocs:pixel-width>499</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr2.jpg</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>129991</xocs:filesize><xocs:pixel-height>844</xocs:pixel-height><xocs:pixel-width>512</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr1.jpg</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>23497</xocs:filesize><xocs:pixel-height>423</xocs:pixel-height><xocs:pixel-width>266</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr7.sml</xocs:attachment-eid><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>5568</xocs:filesize><xocs:pixel-height>119</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr6.sml</xocs:attachment-eid><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6479</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>137</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr5.sml</xocs:attachment-eid><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>5370</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>104</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr4.sml</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>5134</xocs:filesize><xocs:pixel-height>131</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr3.sml</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>7467</xocs:filesize><xocs:pixel-height>109</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr2.sml</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>5682</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>99</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0925443913001385-gr1.sml</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3686</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>103</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc><xocs:refkeys><xocs:refkey3>SERREX2013X1304</xocs:refkey3><xocs:refkey4lp>SERREX2013X1304X1312</xocs:refkey4lp><xocs:refkey4ai>SERREX2013X1304XV</xocs:refkey4ai><xocs:refkey5>SERREX2013X1304X1312XV</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-access-effective-date>2013-07-16T22:19:56Z</xocs:oa-access-effective-date><xocs:oa-sponsor><xocs:oa-sponsor-type>FundingBody</xocs:oa-sponsor-type><xocs:oa-sponsor-name>Wellcome Trust</xocs:oa-sponsor-name></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by/3.0/</xocs:oa-user-license></xocs:open-access></xocs:meta><xocs:serial-item><article xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" version="5.2" docsubtype="fla" xml:lang="en"><item-info><jid>BBADIS</jid><aid>63691</aid><ce:pii>S0925-4439(13)00138-5</ce:pii><ce:doi>10.1016/j.bbadis.2013.04.014</ce:doi><ce:copyright type="other" year="2013">The Authors</ce:copyright></item-info><ce:floats><ce:figure id="f0005"><ce:label>Fig. 1</ce:label><ce:caption id="ca0005"><ce:simple-para id="sp0020" view="all">Steady state levels of the oxidative phosphorylation components and complexes. A. Western blot analysis was performed on cytoplasmic extracts (40<ce:hsp sp="0.25"/>Î¼g) of cultured patient (P) and control (C) fibroblasts to determine steady state levels of COXII (MitoSciences). In the absence of other antibodies to mitochondrially encoded proteins, NDUFB8 (MitoSciences) was monitored as a marker for Complex I. Levels of cytochrome <ce:italic>c</ce:italic> (MitoSciences) and porin (Invitrogen) were determined as controls for the respiratory chain and mitochondrial mass respectively. B. BN-PAGE of mitochondria prepared from cultured skin fibroblasts of patient (P) and control (C) was analyzed by western using antibodies (all MitoSciences) directed against GRIM19, SDHA 70<ce:hsp sp="0.25"/>kDa, Core 2, COXI and F<ce:inf loc="post">1</ce:inf>Î² subunit to identify steady state levels of complexes I, II, III, IV and V respectively.</ce:simple-para></ce:caption><ce:link locator="gr1" id="lk0005"/></ce:figure><ce:figure id="f0010"><ce:label>Fig. 2</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0030" view="all">Microsatellite genotyping and mutation screening. A. Pedigree and haplotypes of the family are given (top to bottom) for loci D17S949, D17S1350, D17S1352, D17S1839, D17S785, D17S784 and D17S928. B. Sequence analysis of <ce:italic>MRPL12</ce:italic> in patient subject (left panel), mother (centre panel) and a control (right panel). The arrow indicates the position of the mutation. Amplification products were sequenced using the PRISM Ready Reaction Sequencing Kit (Perkin-Elmer, Oak Brook, IL) on an automatic sequencer (ABI 3130xl; PE Applied Biosystems, Foster City, CA). <ce:bold>C</ce:bold>. Amino acid alignment of MRPL12 (<ce:italic>H. sapiens</ce:italic> to <ce:italic>S. cerevisiae</ce:italic>) and L7/L12 (<ce:italic>E. coli</ce:italic> to <ce:italic>S. saprophyticus</ce:italic>) proteins. The arrow indicates the conserved amino acid that the <ce:italic>MRPL12</ce:italic> mutation changes from an alanine to a valine. Below * designates identity, whilst and: indicate increasing levels of similarity.</ce:simple-para></ce:caption><ce:link locator="gr2" id="lk0010"/></ce:figure><ce:figure id="f0015"><ce:label>Fig. 3</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0040" view="all">MRPL12 and its position in the ribosome. A. The three dimensional structure of the human MRPL12 (residues 64 to 198) was modeled by comparative protein modeling and energy minimization, using the Swiss-Model program in the automated mode. The 2<ce:hsp sp="0.25"/>Ã coordinate set for the ribosomal protein L12 from <ce:italic>Thermotoga maritima</ce:italic> (PDB code: <ce:inter-ref xlink:href="pdb:1dd3" id="ir0220" xlink:type="simple">1dd3</ce:inter-ref>) was used as a template for modeling the human MRPL12 protein. Swiss-Pdb Viewer 3.7 (<ce:inter-ref xlink:href="http://www.expasy.org/spdbv" id="ir0225" xlink:type="simple">http://www.expasy.org/spdbv</ce:inter-ref>) was used to analyze the structural insight into MRPL12 mutation and visualize the structures. The A181 residue shown (in red) is localized in a helix that is likely to be at the interface of an interaction with translation factors. B. Potential MRPL12 interactions within the ribosomal L7/L12 stalk. Swiss-Pdb Viewer 3.7 (<ce:inter-ref xlink:href="http://www.expasy.org/spdbv" id="ir0230" xlink:type="simple">http://www.expasy.org/spdbv</ce:inter-ref>) was used to superimpose MRPL12 on the <ce:italic>Thermus thermophilus</ce:italic> 70S ribosome (PDB code: <ce:inter-ref xlink:href="pdb:2WRL" id="ir0235" xlink:type="simple">2WRL</ce:inter-ref>) without L7/L12 stalk proteins. MRPL12, L10 and L11 are shown in green, blue and yellow respectively. The Ala181 residue (in red) is located in the MRPL12 CTD. The p.Ala181Val change has a high probability of altering interactions of MRPL12 with elongation factors and might be predicted to affect initial binding, decreasing both rate and accuracy of mitochondrial translation. NTD: N-terminal domain; CTD: C-terminal domain.</ce:simple-para></ce:caption><ce:link locator="gr3" id="lk0015"/></ce:figure><ce:figure id="f0020"><ce:label>Fig. 4</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0050" view="all">Analysis of mitoribosomal components. A. Cell lysates (50<ce:hsp sp="0.25"/>Î¼g) from patient (P) and control (C) fibroblasts were separated by SDS-PAGE followed by western to decorate various components. Polypeptides of the large ribosomal subunit (LSU) included MRPL12 (Eurogentec), MRPL3 (PTG labs), ICT1 (PTG labs) and small ribosomal subunit (SSU) included DAP3 (Abcam), MRPS18B (PTG labs) and MRPS25 (PTG labs). Porin (Invitrogen) was used as a loading control. B. Densitometric values from 3 independent experiments as described in panel A represent the levels of MRPL12, MRPL3, ICT1, DAP3, MRPS18B and MRPS25 in subject compared to control fibroblasts.</ce:simple-para></ce:caption><ce:link locator="gr4" id="lk0020"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 5</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0060" view="all">Isokinetic gradient analysis of mitochondrial lysates. A. Mitochondrial lysates were prepared from patient (P) and control (C) fibroblasts and 300<ce:hsp sp="0.25"/>Î¼g of each was separated through 10-30% (w/v) isokinetic sucrose gradients. The levels of 28S small subunit (SSU) and 39S large subunit (LSU) proteins were determined by western blot analysis. 55S corresponds to the assembled mitoribosome. The steady state level (panel B. porin as loading control) and distribution (panel A) of POLRMT was also examined. Antibodies as in previous legends except POLRMT (Abcam).</ce:simple-para></ce:caption><ce:link locator="gr5" id="lk0025"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 6</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0070" view="all">Mitochondrial protein synthesis. <ce:italic>De novo</ce:italic> synthesis of mitochondrial proteins was determined in patient (P) and control (C) fibroblasts under conditions that inhibited cytosolic translation <ce:cross-ref refid="bb0225" id="cf0005">[45]</ce:cross-ref>. <ce:italic>In vivo</ce:italic> incorporation of <ce:sup loc="post">35</ce:sup>S-methionine/cysteine into mitochondrially encoded proteins was visualised by separation of cell lysate (50<ce:hsp sp="0.25"/>Î¼g) through SDS-PAGE, exposure of the dried gel to a PhosphorImage screen, followed by Storm and ImageQuant analysis (upper panel). To the right of the gel are the aligned densitometric profiles of the patient (lower trace) and control (upper trace). The gel was subsequently rehydrated and stained with Coomassie blue to confirm equal loading (lower panel).</ce:simple-para></ce:caption><ce:link locator="gr6" id="lk0030"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 7</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0080" view="all">Analysis of mitochondrial transcripts and of MRPs immunoprecipitating with MRPL12. A. Steady-state levels of mitochondrial transcripts from patient (P) and control (C) fibroblasts were analyzed by Northern blot. Signals were normalized against 18S cytosolic rRNA. Three different amounts (2, 5 and 10<ce:hsp sp="0.25"/>Î¼g) of total RNAs were loaded. B. MRPL12 was immunoprecipitated from mitochondrial lysates (835<ce:hsp sp="0.25"/>Î¼g) prepared from patient (P) and control (C) fibroblasts. Recovered MRPL12 and co-immunoprecipitating MRPs were analyzed by western blot (antibodies as previously described).</ce:simple-para></ce:caption><ce:link locator="gr7" id="lk0035"/></ce:figure><ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="t0005" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 1</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0085" view="all">Respiratory chain activities in muscle mitochondria, liver homogenate and fibroblasts.</ce:simple-para></ce:caption><tgroup cols="14"><colspec colname="col1"/><colspec colname="col2"/><colspec colname="col3"/><colspec colname="col4"/><colspec colname="col5"/><colspec colname="col6"/><colspec colname="col7"/><colspec colname="col8"/><colspec colname="col9"/><colspec colname="col10"/><colspec colname="col11"/><colspec colname="col12"/><colspec colname="col13"/><colspec colname="col14"/><thead><row valign="top" rowsep="1"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1"/><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col2" nameend="col3" align="left">Muscle mitochondria</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5" align="left">Liver homogenate</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col6" nameend="col8" align="left">Liver homogenate</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col9" nameend="col10" align="left">Fibroblasts</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col11" nameend="col14" align="left">Amniotic cells</entry></row><row valign="top" rowsep="1"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1"/><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">P</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">C</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">P</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">C</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">Twin 1 fetus</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">Twin 2 fetus</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">C</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">P</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">C</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">Twin 1 fetus</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">Twin 2 fetus</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">3rd pregnancy</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">C</entry></row></thead><tbody><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col1" nameend="col14" align="left"><italic>Absolute activities (nmol/min/mg prot)</italic></entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CI</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">17</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">27-44</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CII</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">170</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">75-157</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">63</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">57</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">74-196</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">59</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">33-71</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CIII</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">697</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">494-1004</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">493</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">128-217</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">106</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">73</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">70-236</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">505</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">318-820</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">1.44</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">2.1</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">16.5</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">19-21</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CIV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">374</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">540-1073</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">7</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">131-241</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">57</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">32</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">68-284</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">90</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">189-429</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">0.88</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">0.77</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">32</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">26-36</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">538</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">209-454</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">100</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">53-133</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CI<hsp sp="0.25"/>+<hsp sp="0.25"/>III</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">89</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">113-311</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">27</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">35-67</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CII<hsp sp="0.25"/>+<hsp sp="0.25"/>III</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">443</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">164-357</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">365</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">50-98</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">37</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">23</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">38-104</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">167</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">69-146</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">2.22</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">1.38</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">8.7</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">6.5-8.4</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CS</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">65</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">45</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">40-104</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">293</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">112-264</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col1" nameend="col14" align="left"><vsp sp="0.5"/></entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col1" nameend="col14" align="left"><italic>Activity ratios</italic></entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CIV/CI<hsp sp="0.25"/>+<hsp sp="0.25"/>III</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">4.2</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">3.4<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.8</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CIV/CII<hsp sp="0.25"/>+<hsp sp="0.25"/>III</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">0.8</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">3.1<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.5</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">0.01</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">3.0<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.4</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">1.5</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">1.39</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">2.7<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.3</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">0.5</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">3.0<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.2</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">0.61</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">0.55</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">3.6</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">2.1-3.3</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CIV/CI</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">5.4</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">10.1<hsp sp="0.25"/>Â±<hsp sp="0.25"/>1.0</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CIV/CII</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">1.5</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">6.1<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.7</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CIV/CIII</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">0.5</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">1.5<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.2</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">0.01</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">2.0<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.6</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">0.54</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">0.4</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">1.2<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.1</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">0.2</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">0.6<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.04</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">0.39</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">0.37</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">1.9</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">0.7-1.2</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">CIV/CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">0.7</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">2.5<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.8</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">0.9</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">3.5<hsp sp="0.25"/>Â±<hsp sp="0.25"/>0.4</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">-</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">-</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0090" view="all">CI-CV, complexes I-V; CS, citrate synthase; P, subject; C, control. Abnormal activity values and ratios are shown in bold.</ce:simple-para><ce:simple-para id="sp0095" view="all">Spectrophotometric assays of respiratory chain and complex V enzymes were carried out as previously described <ce:cross-ref refid="bb0210" id="cf0010">[42]</ce:cross-ref>. Haemoglobin contamination of amniotic cells reduced accuracy of the absolute values of RC complex activities but not the ratios.</ce:simple-para></ce:legend></ce:table></ce:floats><head><ce:article-footnote><ce:label>â</ce:label><ce:note-para id="np9005" view="all">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</ce:note-para></ce:article-footnote><ce:title id="ti0005">Mutations in mitochondrial ribosomal protein MRPL12 leads to growth retardation, neurological deterioration and mitochondrial translation deficiency</ce:title><ce:author-group id="ag0005"><ce:author id="au0005"><ce:given-name>ValÃ©rie</ce:given-name><ce:surname>Serre</ce:surname><ce:cross-ref refid="af0005" id="cf0015"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="fn0005" id="cf0025"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:e-address id="em0005" type="email">serre@ijm.univ-paris-diderot.fr</ce:e-address></ce:author><ce:author id="au0010"><ce:given-name>Agata</ce:given-name><ce:surname>Rozanska</ce:surname><ce:cross-ref refid="af0015" id="cf0030"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="fn0005" id="cf0035"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:e-address id="em0010" type="email">agata.rozanska@newcastle.ac.uk</ce:e-address></ce:author><ce:author id="au0015"><ce:given-name>Marine</ce:given-name><ce:surname>Beinat</ce:surname><ce:cross-ref refid="af0005" id="cf0040"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0015" type="email">marine.beinat@inserm.fr</ce:e-address></ce:author><ce:author id="au0020"><ce:given-name>Dominique</ce:given-name><ce:surname>Chretien</ce:surname><ce:cross-ref refid="af0005" id="cf0050"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0020" type="email">dominique.chretien@inserm.fr</ce:e-address></ce:author><ce:author id="au0025"><ce:given-name>Nathalie</ce:given-name><ce:surname>Boddaert</ce:surname><ce:cross-ref refid="af0005" id="cf0060"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0025" type="email">nathalie.boddaert@nck.aphp.fr</ce:e-address></ce:author><ce:author id="au0030"><ce:given-name>Arnold</ce:given-name><ce:surname>Munnich</ce:surname><ce:cross-ref refid="af0005" id="cf0070"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0030" type="email">arnold.munnich@inserm.fr</ce:e-address></ce:author><ce:author id="au0035"><ce:indexed-name>Rotig</ce:indexed-name><ce:given-name>AgnÃ¨s</ce:given-name><ce:surname>RÃ¶tig</ce:surname><ce:cross-ref refid="af0005" id="cf0080"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0010" id="cf0085"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0010" id="cf0095"><ce:sup loc="post">ââ</ce:sup></ce:cross-ref><ce:e-address id="em0035" type="email">agnes.rotig@inserm.fr</ce:e-address></ce:author><ce:author id="au0040"><ce:given-name>Zofia M.</ce:given-name><ce:surname>Chrzanowska-Lightowlers</ce:surname><ce:cross-ref refid="af0015" id="cf0100"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0005" id="cf1095"><ce:sup loc="post">â</ce:sup></ce:cross-ref><ce:e-address id="em0040" type="email">Zofia.Chrzanowska-Lightowlers@ncl.ac.uk</ce:e-address></ce:author><ce:affiliation id="af0005"><ce:label>a</ce:label><ce:textfn id="tn0005">UniversitÃ© Paris Descartes-Sorbonne Paris CitÃ©, Institut Imagine and INSERM U781, HÃ´pital Necker-Enfants Malades, 149 rue de SÃ¨vres, 75015 Paris, France</ce:textfn><sa:affiliation><sa:organization>UniversitÃ© Paris Descartes-Sorbonne Paris CitÃ©</sa:organization><sa:organization>Institut Imagine and INSERM U781</sa:organization><sa:organization>HÃ´pital Necker-Enfants Malades</sa:organization><sa:address-line>149 rue de SÃ¨vres</sa:address-line><sa:city>Paris</sa:city><sa:postal-code>75015</sa:postal-code><sa:country>France</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0010"><ce:label>b</ce:label><ce:textfn id="tn0010">Department of Pediatrics, HÃ´pital Necker-Enfants-Malades, 149 rue de SÃ¨vres, 75015 Paris, France</ce:textfn><sa:affiliation><sa:organization>Department of Pediatrics</sa:organization><sa:organization>HÃ´pital Necker-Enfants-Malades</sa:organization><sa:address-line>149 rue de SÃ¨vres</sa:address-line><sa:city>Paris</sa:city><sa:postal-code>75015</sa:postal-code><sa:country>France</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0015"><ce:label>c</ce:label><ce:textfn id="tn0015">Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, Newcastle University, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom</ce:textfn><sa:affiliation><sa:organization>Wellcome Trust Centre for Mitochondrial Research</sa:organization><sa:organization>Institute for Ageing and Health</sa:organization><sa:organization>Newcastle University</sa:organization><sa:organization>Medical School</sa:organization><sa:address-line>Framlington Place</sa:address-line><sa:city>Newcastle upon Tyne</sa:city><sa:postal-code>NE2 4HH</sa:postal-code><sa:country>United Kingdom</sa:country></sa:affiliation></ce:affiliation><ce:correspondence id="cr0005"><ce:label>â</ce:label><ce:text id="tx0005">Correspondence to: Z.M. Chrzanowska-Lightowlers, Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, Newcastle University, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom. Tel.: +<ce:hsp sp="0.10"/>44191 222 8028; fax: +<ce:hsp sp="0.10"/>44 191 222 5685.</ce:text></ce:correspondence><ce:correspondence id="cr0010"><ce:label>ââ</ce:label><ce:text id="tx9015">Correspondence to: A. RÃ¶tig, UniversitÃ© Paris Descartes-Sorbonne Paris CitÃ©, Institut Imagine and INSERM U781, HÃ´pital Necker-Enfants Malades, 149 rue de SÃ¨vres, 75015 Paris, France. Tel.: +<ce:hsp sp="0.10"/>33 1 44 38 15 84; fax: +<ce:hsp sp="0.10"/>33 1 47 34 85 14.</ce:text></ce:correspondence><ce:footnote id="fn0005"><ce:label>1</ce:label><ce:note-para id="np0005" view="all">V.S. and A.R. are joint first authors.</ce:note-para></ce:footnote></ce:author-group><ce:date-received day="15" month="2" year="2013"/><ce:date-revised day="25" month="3" year="2013"/><ce:date-accepted day="10" month="4" year="2013"/><ce:abstract id="ab0005" view="all" class="author"><ce:section-title id="st0005">Abstract</ce:section-title><ce:abstract-sec id="as0005" view="all"><ce:simple-para id="sp0005" view="all">Multiple respiratory chain deficiencies represent a common cause of mitochondrial diseases and are associated with a wide range of clinical symptoms. We report a subject, born to consanguineous parents, with growth retardation and neurological deterioration. Multiple respiratory chain deficiency was found in muscle and fibroblasts of the subject as well as abnormal assembly of complexes I and IV. A microsatellite genotyping of the family members detected only one region of homozygosity on chromosome 17q24.2-q25.3 in which we focused our attention to genes involved in mitochondrial translation. We sequenced <ce:italic>MRPL12</ce:italic>, encoding the mitochondrial ribosomal protein L12 and identified a c.542C&gt;T transition in exon 5 changing a highly conserved alanine into a valine (p.Ala181Val). This mutation resulted in a decreased steady-state level of MRPL12 protein, with altered integration into the large ribosomal subunit. Moreover, an overall mitochondrial translation defect was observed in the subject's fibroblasts with a significant reduction of synthesis of COXI, COXII and COXIII subunits. Modeling of MRPL12 shows Ala181 positioned in a helix potentially involved in an interface of interaction suggesting that the p.Ala181Val change might be predicted to alter interactions with the elongation factors. These results contrast with the eubacterial orthologues of human MRPL12, where L7/L12 proteins do not appear to have a selective effect on translation. Therefore, analysis of the mutated version found in the subject presented here suggests that the mammalian protein does not function in an entirely analogous manner to the eubacterial L7/L12 equivalent.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="author-highlights" id="ab0010" view="all"><ce:section-title id="st0010">Highlights</ce:section-title><ce:abstract-sec id="as0010" view="all"><ce:simple-para id="sp0010" view="all"><ce:list id="l0005"><ce:list-item id="u0005"><ce:label>â¢</ce:label><ce:para id="p0150" view="all">MRPL12 function is not entirely analogous to the eubacterial L7/L12 equivalent.</ce:para></ce:list-item><ce:list-item id="u0010"><ce:label>â¢</ce:label><ce:para id="p0155" view="all">Mutations in MRPL12 cause translation defects.</ce:para></ce:list-item><ce:list-item id="u0015"><ce:label>â¢</ce:label><ce:para id="p0160" view="all">Mutations in apparently universal translation factors can affect different OXPHOS complexes.</ce:para></ce:list-item></ce:list></ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id="ks0005" class="abr" view="all"><ce:section-title id="st0015">Abbreviations</ce:section-title><ce:keyword id="kw0070"><ce:text id="tx0015">MRP</ce:text><ce:keyword id="kw0075"><ce:text id="tx0020">mitoribosomal protein</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0080"><ce:text id="tx0025">OXPHOS</ce:text><ce:keyword id="kw0085"><ce:text id="tx0030">oxidative phosphorylation</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0090"><ce:text id="tx0035">COX</ce:text><ce:keyword id="kw0095"><ce:text id="tx0040">cytochrome <ce:italic>c</ce:italic> oxidase</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0100"><ce:text id="tx0045">POLRMT</ce:text><ce:keyword id="kw0105"><ce:text id="tx0050">mitochondrial RNA polymerase</ce:text></ce:keyword></ce:keyword></ce:keywords><ce:keywords id="ks0010" view="all" class="keyword"><ce:section-title id="st0020">Keywords</ce:section-title><ce:keyword id="kw0110"><ce:text id="tx0055">Mitochondria</ce:text></ce:keyword><ce:keyword id="kw0115"><ce:text id="tx0060">Mitoribosome</ce:text></ce:keyword><ce:keyword id="kw0120"><ce:text id="tx0065">Protein synthesis</ce:text></ce:keyword><ce:keyword id="kw0125"><ce:text id="tx0070">Disease</ce:text></ce:keyword><ce:keyword id="kw0130"><ce:text id="tx0075">OXPHOS defect</ce:text></ce:keyword></ce:keywords></head><body view="all"><ce:sections><ce:section id="s0005" view="all"><ce:label>1</ce:label><ce:section-title id="st0025">Introduction</ce:section-title><ce:para id="p0005" view="all">The mitochondrial machinery responsible for oxidative phosphorylation (OXPHOS) comprises five enzyme complexes containing approximately 80 proteins of which only 13 are encoded by the mitochondrial genome (mtDNA) <ce:cross-ref refid="bb0005" id="cf0110">[1]</ce:cross-ref>. OXPHOS deficiencies affecting a single or multiple complexes can result from mutations in either mitochondrial or nuclear genes and are associated with a variety of disease mechanisms <ce:cross-refs refid="bb0010 bb0015" id="cf0115">[2,3]</ce:cross-refs>. With the advent of Next Generation Sequencing there is an increasing number of pathogenic mutations being identified that are not solely restricted to the 80 genes encoding OXPHOS components, thus highlighting the importance of mechanisms impacting on mitochondrial gene expression <ce:cross-refs refid="bb0020 bb0025" id="cf0120">[4,5]</ce:cross-refs>. Combined OXPHOS deficiencies can arise from alterations in mtDNA, its maintenance <ce:cross-ref refid="bb0030" id="cf0125">[6]</ce:cross-ref>, cardiolipin levels <ce:cross-refs refid="bb0035 bb0040" id="cf0130">[7,8]</ce:cross-refs>, or where none of these are affected, from direct defects in synthesis of mitochondrially encoded proteins <ce:cross-ref refid="bb0045" id="cf0135">[9]</ce:cross-ref>. This last group constitutes a heterogeneous mix of patients suffering from a wide range of clinical symptoms making clinical diagnosis difficult <ce:cross-ref refid="bb0050" id="cf0140">[10]</ce:cross-ref>. Genetic diagnosis is yet more elusive in children with mitochondrial disease where unidentified nuclear mutations account for the majority of cases <ce:cross-ref refid="bb0055" id="cf0145">[11]</ce:cross-ref>. This diagnostic problem is compounded by our relatively poor understanding of the complex molecular machinery that drives translation in mitochondria. This machinery comprises over a hundred proteins <ce:cross-ref refid="bb0060" id="cf0150">[12]</ce:cross-ref>, all of which are putative candidate genes for translation deficiencies in human. Indeed, translation deficiencies represent a growing cause of multiple OXPHOS deficiencies with several published pathogenic mutations in genes related to the intra-organellar protein synthesis. Although many mutations associated with impaired mitochondrial translation currently map to tRNA genes <ce:cross-ref refid="bb0065" id="cf0155">[13]</ce:cross-ref> and a few ribosomal RNA (rRNA) <ce:cross-ref refid="bb0070" id="cf0160">[14]</ce:cross-ref>, the list of nuclear gene mutations is steadily growing as mutations in genes encoding mitochondrial translation factors such as <ce:italic>GFM1</ce:italic> (OMIM: <ce:inter-ref xlink:href="omim:606639" id="ir0240" xlink:type="simple">606639</ce:inter-ref>) <ce:cross-refs refid="bb0075 bb0080" id="cf0165">[15,16]</ce:cross-refs>, <ce:italic>TSFM</ce:italic> (OMIM: <ce:inter-ref xlink:href="omim:604723" id="ir0245" xlink:type="simple">604723</ce:inter-ref>) <ce:cross-ref refid="bb0085" id="cf0170">[17]</ce:cross-ref> and <ce:italic>TUFM</ce:italic> (OMIM: <ce:inter-ref xlink:href="omim:602389" id="ir0250" xlink:type="simple">602389</ce:inter-ref>) <ce:cross-ref refid="bb0090" id="cf0175">[18]</ce:cross-ref>; mitochondrial aminoacyl-tRNA synthetases (RARS2 (OMIM: <ce:inter-ref xlink:href="omim:611524" id="ir0255" xlink:type="simple">611524</ce:inter-ref>) <ce:cross-ref refid="bb0095" id="cf0180">[19]</ce:cross-ref>, DARS2 (OMIM: <ce:inter-ref xlink:href="omim:610956" id="ir0260" xlink:type="simple">610956</ce:inter-ref>) <ce:cross-ref refid="bb0100" id="cf0185">[20]</ce:cross-ref>, YARS2 (OMIM: <ce:inter-ref xlink:href="omim:610957" id="ir0265" xlink:type="simple">610957</ce:inter-ref>) <ce:cross-ref refid="bb0105" id="cf0190">[21]</ce:cross-ref>, SARS2 (OMIM: <ce:inter-ref xlink:href="omim:612804" id="ir0270" xlink:type="simple">612804</ce:inter-ref>) <ce:cross-ref refid="bb0110" id="cf0195">[22]</ce:cross-ref>, HARS2 (OMIM: <ce:inter-ref xlink:href="omim:600783" id="ir0275" xlink:type="simple">600783</ce:inter-ref>) <ce:cross-ref refid="bb0115" id="cf0200">[23]</ce:cross-ref>, AARS2 (OMIM: <ce:inter-ref xlink:href="omim:612035" id="ir0280" xlink:type="simple">612035</ce:inter-ref>) <ce:cross-ref refid="bb0120" id="cf0205">[24]</ce:cross-ref>, MARS2 (OMIM: <ce:inter-ref xlink:href="omim:609728" id="ir0285" xlink:type="simple">609728</ce:inter-ref>) <ce:cross-ref refid="bb0125" id="cf0210">[25]</ce:cross-ref>, EARS2 (OMIM: <ce:inter-ref xlink:href="omim:612799" id="ir0290" xlink:type="simple">612799</ce:inter-ref>) <ce:cross-ref refid="bb0130" id="cf0215">[26]</ce:cross-ref>), FARS2 (OMIM: <ce:inter-ref xlink:href="omim:611592" id="ir0295" xlink:type="simple">611592</ce:inter-ref>) <ce:cross-ref refid="bb0135" id="cf0220">[27]</ce:cross-ref>; tRNA-modifying enzymes (PUS1 (OMIM: <ce:inter-ref xlink:href="omim:608109" id="ir0300" xlink:type="simple">608109</ce:inter-ref>) <ce:cross-ref refid="bb0140" id="cf0225">[28]</ce:cross-ref>, TRMU (OMIM: <ce:inter-ref xlink:href="omim:610230" id="ir0305" xlink:type="simple">610230</ce:inter-ref>) <ce:cross-ref refid="bb0145" id="cf0230">[29]</ce:cross-ref>, MTO1 (OMIM: <ce:inter-ref xlink:href="omim:614667" id="ir0310" xlink:type="simple">614667</ce:inter-ref>) <ce:cross-ref refid="bb0150" id="cf0235">[30]</ce:cross-ref>); other factors (C12orf65 (OMIM: <ce:inter-ref xlink:href="omim:613541" id="ir0315" xlink:type="simple">613541</ce:inter-ref>) <ce:cross-ref refid="bb0155" id="cf0240">[31]</ce:cross-ref>, TACO1 (OMIM: <ce:inter-ref xlink:href="omim:612958" id="ir0320" xlink:type="simple">612958</ce:inter-ref>) <ce:cross-ref refid="bb0160" id="cf0245">[32]</ce:cross-ref>, LRPPRC (OMIM: <ce:inter-ref xlink:href="omim:607544" id="ir0325" xlink:type="simple">607544</ce:inter-ref>) <ce:cross-ref refid="bb0165" id="cf0250">[33]</ce:cross-ref>, C12orf62 (OMIM: <ce:inter-ref xlink:href="omim:614478" id="ir0330" xlink:type="simple">614478</ce:inter-ref>) <ce:cross-ref refid="bb0170" id="cf0255">[34]</ce:cross-ref>) and mitochondrial ribosomal proteins (MRPS16 (OMIM: <ce:inter-ref xlink:href="omim:609204" id="ir0335" xlink:type="simple">609204</ce:inter-ref>) <ce:cross-ref refid="bb0175" id="cf0260">[35]</ce:cross-ref>, MRPS22 (OMIM: <ce:inter-ref xlink:href="omim:605810" id="ir0340" xlink:type="simple">605810</ce:inter-ref>) <ce:cross-ref refid="bb0180" id="cf0265">[36]</ce:cross-ref>, MRPL3 (OMIM: <ce:inter-ref xlink:href="omim:607118" id="ir0345" xlink:type="simple">607118</ce:inter-ref>) <ce:cross-ref refid="bb0025" id="cf0270">[5]</ce:cross-ref>) have been successively reported (reviewed in Ref. <ce:cross-ref refid="bb0070" id="cf0275">[14]</ce:cross-ref>). Relatively few cases of OXPHOS deficiencies associated with mutations in mitochondrial ribosomal proteins (MRPs) have been described so far. <ce:italic>MRPS16</ce:italic> mutations have been described in only one family with agenesis of corpus callosum and dysmorphism. <ce:italic>MRPS22</ce:italic> mutations lead to cardiomyopathy, hypotonia and tubulopathy in a first family and Cornelia de Lange-like dysmorphic features, brain abnormalities and hypertrophic cardiomyopathy in another family. Finally, we recently identified <ce:italic>MRPL3</ce:italic> mutations in four siblings of the same family presenting cardiomyopathy and psychomotor retardation. Since the mammalian mitoribosome (55S) is ~<ce:hsp sp="0.10"/>2<ce:hsp sp="0.25"/>megadalton machine consisting of approximately 80 components that make up the 28S small (SSU) and 39S large subunit (LSU), it is likely that more pathogenic mutations in the constituent polypeptides will be uncovered. One of the substantial differences between the mammalian mitoribosome and those of eubacteria (70S) or the eukaryotic cytosol (80S) is the reversal in the protein to rRNA ratio. The 70S and 80S particles contain ~<ce:hsp sp="0.10"/>70% rRNA, whilst human mitoribosomes contain ~<ce:hsp sp="0.10"/>70% protein. This change in the ratio represents both an acquisition of new MRPs as well as loss of bacterial orthologues <ce:cross-refs refid="bb0185 bb0190" id="cf0280">[37,38]</ce:cross-refs>. MRPL12 does have a bacterial orthologue, which through its interactions with translation factors is important in protein synthesis regulating both speed and accuracy <ce:cross-refs refid="bb0195 bb0200 bb0205" id="cf0285">[39-41]</ce:cross-refs>.</ce:para><ce:para id="p0010" view="all">Here we investigate the genetic basis of disease in a subject born to consanguineous parents, who initially presented with growth retardation and then neurological distress, with evidence of compromised mitochondrial protein synthesis. We have identified the causative mutation to be in <ce:italic>MRPL12</ce:italic>, encoding a protein of the large subunit of mitochondrial ribosome. This is an important finding indicating that the function and consequence of dysfunction cannot automatically be extrapolated from an apparent orthologue. We show that proteins involved in mitochondrial translation, even close orthologues as submitted here, can defy predictions. Moreover, mutations in such genes that should affect all mitochondrially encoded gene products can exert respiratory chain complex specific defects.</ce:para></ce:section><ce:section id="s0010" view="all"><ce:label>2</ce:label><ce:section-title id="st0030">Materials and methods</ce:section-title><ce:section id="s0015" view="all"><ce:label>2.1</ce:label><ce:section-title id="st0035">Analysis of oxidative phosphorylation activities</ce:section-title><ce:para id="p0015" view="all">Spectrophotometric assays of respiratory chain and complex V enzymes were carried out as previously described <ce:cross-ref refid="bb0210" id="cf0290">[42]</ce:cross-ref>. Mitochondrial suspension from cultured skin fibroblasts was obtained after suspending 50<ce:hsp sp="0.25"/>Î¼l of frozen cells in 1<ce:hsp sp="0.25"/>ml of mitochondria extraction medium (20<ce:hsp sp="0.25"/>mM Tris-HCl (pH 7.2), 250<ce:hsp sp="0.25"/>mM sucrose, 2<ce:hsp sp="0.25"/>mM EGTA, 40<ce:hsp sp="0.25"/>mM KCl, 1<ce:hsp sp="0.25"/>mg/ml BSA) supplemented with 0.01% (w/v) digitonin and 10% Percoll (v/v). After 10<ce:hsp sp="0.25"/>min at 4<ce:hsp sp="0.25"/>Â°C, the sample was pelleted, washed in extraction medium and pelleted before resuspension in 30<ce:hsp sp="0.25"/>Î¼l of extraction medium for respiratory chain enzyme measurements.</ce:para></ce:section><ce:section id="s0020" view="all"><ce:label>2.2</ce:label><ce:section-title id="st0040">Microsatellite genotyping and mutation screening</ce:section-title><ce:para id="p0020" view="all">A genome-wide search for homozygosity was undertaken with 382 pairs of fluorescent oligonucleotides from the Genescan Linkage Mapping Set, version II (Perkin-Elmer) under conditions recommended by the manufacturer. Amplified fragments were electrophoresed and analyzed with an automatic sequencer (ABI 377). The polymorphic markers had an average spacing of 10<ce:hsp sp="0.25"/>cM throughout the genome.</ce:para><ce:para id="p0025" view="all">Genes encoding mitochondrial proteins were selected in Mitocarta <ce:cross-ref refid="bb0215" id="cf0295">[43]</ce:cross-ref>. The exons and exon-intron boundaries of the <ce:italic>MRPL12</ce:italic> gene were amplified using specific primers (sequences available on request) with initial denaturation at 96<ce:hsp sp="0.25"/>Â°C - 5<ce:hsp sp="0.25"/>min, followed by 30 cycles of 96<ce:hsp sp="0.25"/>Â°C - 30<ce:hsp sp="0.25"/>s, 55<ce:hsp sp="0.25"/>Â°C - 30<ce:hsp sp="0.25"/>s, 72<ce:hsp sp="0.25"/>Â°C - 30<ce:hsp sp="0.25"/>s, and a last extension at 72<ce:hsp sp="0.25"/>Â°C for 10<ce:hsp sp="0.25"/>min. Amplification products were purified by ExoSapIT (Amersham, Buckinghamshire, UK) and directly sequenced using the PRISM Ready Reaction Sequencing Kit (Perkin-Elmer, Oak Brook, IL) on an automatic sequencer (ABI 3130xl; PE Applied Biosystems, Foster City, CA).</ce:para></ce:section><ce:section id="s0025" view="all"><ce:label>2.3</ce:label><ce:section-title id="st0045">Cell culture</ce:section-title><ce:para id="p0030" view="all">Human skin fibroblasts were cultured in DMEM medium (Dulbecco's modified Eagle's medium, Gibco) supplemented with 10% (v/v) fetal calf serum (FCS), 2<ce:hsp sp="0.25"/>mM <ce:small-caps>l</ce:small-caps>-glutamine, 50<ce:hsp sp="0.25"/>Î¼g/ml uridine, 110<ce:hsp sp="0.25"/>Î¼g/ml pyruvate, 10,000<ce:hsp sp="0.25"/>U/ml penicillin G and 10,000<ce:hsp sp="0.25"/>Î¼g/ml streptomycin.</ce:para></ce:section><ce:section id="s0030" view="all"><ce:label>2.4</ce:label><ce:section-title id="st0050">Protein analysis</ce:section-title><ce:para id="p0035" view="all">For blue native-polyacrylamide gel electrophoresis (BN-PAGE), mitochondria and OXPHOS complexes were isolated as described <ce:cross-ref refid="bb0220" id="cf0300">[44]</ce:cross-ref>. Solubilized OXPHOS proteins (20<ce:hsp sp="0.25"/>Î¼g) were loaded on a 4-16% (w/v) polyacrylamide non-denaturing gradient gel (Invitrogen). SDS-PAGE analysis was performed on either solubilized mitochondrial proteins (40<ce:hsp sp="0.25"/>Î¼g) or cell lysate (50<ce:hsp sp="0.25"/>Î¼g) extracted from cultured skin fibroblasts. After electrophoresis, gels were transferred to a PVDF membrane (GE-Healthcare) and processed for immunoblotting.</ce:para></ce:section><ce:section id="s0035" view="all"><ce:label>2.5</ce:label><ce:section-title id="st0055">Metabolic labelling of mitochondrial translation products</ce:section-title><ce:para id="p0040" view="all"><ce:italic>In vitro</ce:italic> labeling of mitochondrial translation products was a modification from Chomyn et al. <ce:cross-ref refid="bb0225" id="cf0305">[45]</ce:cross-ref>. Essentially, cultured skin fibroblasts were preincubated in methionine/cysteine-free DMEM (2<ce:hsp sp="0.25"/>Ã<ce:hsp sp="0.25"/>10<ce:hsp sp="0.25"/>min) followed by a 10<ce:hsp sp="0.25"/>min in the presence of emetine (100<ce:hsp sp="0.25"/>Î¼g/ml). Radiolabel (125<ce:hsp sp="0.25"/>Î¼Ci/ml EasyTagâ¢ express<ce:sup loc="post">35</ce:sup>S protein labelling mix - NEG772002MC, PerkinElmer) was then added for 1<ce:hsp sp="0.25"/>h at 37<ce:hsp sp="0.25"/>Â°C and chased for 1<ce:hsp sp="0.25"/>h. Cells were harvested in cold 1<ce:hsp sp="0.25"/>mM EDTA/PBS, washed 3 times in cold PBS and the pellet resuspended in 30<ce:hsp sp="0.25"/>Î¼l PBS containing 1<ce:hsp sp="0.10"/>Ã EDTA free protease inhibitors (Roche) and 1<ce:hsp sp="0.25"/>mM PMSF. Samples were treated with 2<ce:hsp sp="0.10"/>Ã dissociation buffer (20% (v/v) glycerol, 4% (w/v) SDS, 250<ce:hsp sp="0.25"/>mM Tris-HCl pH 6.8, 100<ce:hsp sp="0.25"/>mM DTT) and 12<ce:hsp sp="0.25"/>U Benzonase nuclease (Novagen) for 1<ce:hsp sp="0.25"/>h and separated on a 15% (w/v) SDS-PAGE. The gel was fixed overnight (3% (v/v) glycerol, 10% (v/v) acetic acid, 30% (v/v) methanol) and vacuum dried (60<ce:hsp sp="0.25"/>Â°C, 2<ce:hsp sp="0.25"/>h). Radiolabelled proteins were visualized by PhosphorImage and analyzed with Image-Quant software (Molecular Dynamics, GE Healthcare).</ce:para></ce:section><ce:section id="s0040" view="all"><ce:label>2.6</ce:label><ce:section-title id="st0060">Homology modeling of the human MRPL12 protein</ce:section-title><ce:para id="p0045" view="all">The three dimensional structure of the human MRPL12 (residues 64 to 198) was modeled by comparative protein modeling and energy minimization, using the Swiss-Model program (<ce:inter-ref xlink:href="http://swissmodel.expasy.org/" id="ir0350" xlink:type="simple">http://swissmodel.expasy.org/</ce:inter-ref>) in the automated mode. The 2<ce:hsp sp="0.25"/>Ã coordinate set for the ribosomal protein L12 from <ce:italic>Thermotoga maritima</ce:italic> (PDB code: <ce:inter-ref xlink:href="pdb:1dd3" id="ir0355" xlink:type="simple">1dd3</ce:inter-ref>) was used as a template for modeling the human MRPL12 protein. Swiss-Pdb Viewer 3.7 (<ce:inter-ref xlink:href="http://www.expasy.org/spdbv" id="ir0360" xlink:type="simple">http://www.expasy.org/spdbv</ce:inter-ref>) was used to analyze the structural insight into MRPL12 mutation and visualize the structures.</ce:para></ce:section><ce:section id="s0045" view="all"><ce:label>2.7</ce:label><ce:section-title id="st0065">Cell lysates, Westerns and isokinetic sucrose gradients</ce:section-title><ce:para id="p0050" view="all">Cell lysates were prepared from fibroblasts by addition of cold lysis buffer (50<ce:hsp sp="0.25"/>mM Tris-HCl pH 7.5, 130<ce:hsp sp="0.25"/>mM NaCl, 2<ce:hsp sp="0.25"/>mM MgCl<ce:inf loc="post">2</ce:inf>, 1<ce:hsp sp="0.25"/>mM PMSF, 1% (v/v) NP-40) to cell pellets, which were vortexed for 30<ce:hsp sp="0.25"/>s, centrifuged at 600<ce:hsp sp="0.25"/><ce:italic>g</ce:italic> for 2<ce:hsp sp="0.25"/>min (4<ce:hsp sp="0.25"/>Â°C) to remove nuclei and the supernatant retained. These were used for standard westerns as described <ce:cross-ref refid="bb0230" id="cf0310">[46]</ce:cross-ref>. Mitochondria were prepared as above and lyzed in 50<ce:hsp sp="0.25"/>mM Tris-HCl pH 7.4, 150<ce:hsp sp="0.25"/>mM NaCl, 1<ce:hsp sp="0.25"/>mM EDTA, 1% Triton X-100, protease inhibitor mix (EDTA free, Roche), 1<ce:hsp sp="0.25"/>mM PMSF, 10<ce:hsp sp="0.25"/>mM MgCl<ce:inf loc="post">2</ce:inf>. Mitochondrial lysates (0.3<ce:hsp sp="0.25"/>mg) were loaded on a isokinetic sucrose gradient (1<ce:hsp sp="0.25"/>ml 10-30% (v/v)) in 50<ce:hsp sp="0.25"/>mM Tris-HCl (pH 7.2), 10<ce:hsp sp="0.25"/>mM Mg(OAc)<ce:inf loc="post">2</ce:inf>, 40<ce:hsp sp="0.25"/>mM NH<ce:inf loc="post">4</ce:inf>Cl, 0.1<ce:hsp sp="0.25"/>M KCl, 1<ce:hsp sp="0.25"/>mM PMSF, 50<ce:hsp sp="0.25"/>Î¼g/ml chloramphenicol), and centrifuged for 2<ce:hsp sp="0.25"/>h 15<ce:hsp sp="0.25"/>min at 100,000<ce:hsp sp="0.25"/><ce:italic>g</ce:italic> at 4<ce:hsp sp="0.25"/>Â°C. Fractions (100<ce:hsp sp="0.25"/>Î¼l) were collected and 10<ce:hsp sp="0.25"/>Î¼l aliquots were analyzed directly by western blotting <ce:cross-ref refid="bb0235" id="cf0315">[47]</ce:cross-ref>.</ce:para><ce:para id="p0055" view="all">Immunodetection was performed using the following primary antibodies: anti-CI-Grim19, CII-SDHA 70<ce:hsp sp="0.25"/>kDa, CIII-core2, CIV-COXI, CIV-COXII, CV-subunit Î², cyt <ce:italic>c</ce:italic>, NDUFB8 (mouse monoclonal antibodies, MitoSciences); anti-MRPL3 goat polyclonal, MRPS18B rabbit polyclonal, MRPS25 rabbit polyclonal and ICT1 rabbit polyclonal antibodies (Protein Tech Group, Inc., Chicago); anti-DAP3 mouse monoclonal, POLRMT rabbit polyclonal (Abcam); and anti-Porin, mouse monoclonal antibodies (Invitrogen). Anti-MRPL12 rabbit polyclonal antibody was custom made (Eurogentec). Secondary antibody detection was performed using peroxidase-conjugated anti-rabbit, anti-goat or anti-mouse IgG (Abcam or Dako). The signal was generated using ECL<ce:hsp sp="0.10"/>+ (Pierce, Rockford, USA) and visualised by phosphorimaging and analyzed by ImageQuant software.</ce:para></ce:section><ce:section id="s0050" view="all"><ce:label>2.8</ce:label><ce:section-title id="st0070">RNA and Northern blotting</ce:section-title><ce:para id="p0060" view="all">RNA was isolated from fibroblasts using Trizol following manufacturer's protocol (Invitrogen). Northern blots were performed as described <ce:cross-ref refid="bb0240" id="cf0320">[48]</ce:cross-ref>. Briefly, aliquots of RNA (5<ce:hsp sp="0.25"/>Î¼g) were electrophoresed through 1.2% (w/v) agarose under denaturing conditions and transferred to GenescreenPlus membrane (NEN duPont) following the manufacturer's protocol. Radiolabelled probes were generated using random hexamers on PCR-generated templates corresponding to internal regions of the relevant genes.</ce:para></ce:section></ce:section><ce:section id="s0055" view="all"><ce:label>3</ce:label><ce:section-title id="st0075">Results and discussion</ce:section-title><ce:section id="s0060" view="all"><ce:label>3.1</ce:label><ce:section-title id="st0080">Clinical report</ce:section-title><ce:para id="p0065" view="all">The subject, a boy, was born to first cousin Roma/Gypsy parents by cesarean section, at 41<ce:hsp sp="0.25"/>weeks of pregnancy with severe general hypotrophy (birth weight 2250<ce:hsp sp="0.25"/>g, height 48<ce:hsp sp="0.25"/>cm, Occipitofrontal Circumference 34<ce:hsp sp="0.25"/>cm). His clinical examination at birth was normal and initial investigations failed to identify the cause of his severe hypotrophy (normal blood caryotype, heart ultrasound, bone age, CT scan and metabolic workup). He failed to thrive thereafter and was repeatedly admitted in the first 12<ce:hsp sp="0.25"/>months for gradual worsening of his condition (weight and height: -<ce:hsp sp="0.10"/>4SD, OFC: -<ce:hsp sp="0.10"/>2SD). Clinical examination at 10<ce:hsp sp="0.25"/>months showed severe denutrition, muscle weakness but detectable deep tendon reflexes and no major trunk hypotonia. He started walking with aid at 12<ce:hsp sp="0.25"/>months. Basal growth hormone (GH) levels in plasma were normal (0.5<ce:hsp sp="0.25"/>ng/ml) but plasma IGF1 was very low (0.07<ce:hsp sp="0.25"/>U/ml, normal 0.2). Stimulation by ornithine triggered an adequate elevation of plasma GH with correction of plasma IGF1 (GH: 46.9<ce:hsp sp="0.25"/>ng/ml, IGF1: 0.2<ce:hsp sp="0.25"/>U/ml, and 0.45<ce:hsp sp="0.25"/>U/ml following GH administration). These results ruled out a dwarfism of endocrine origin. Yet, high plasma lactate (3.5 to 4.4<ce:hsp sp="0.25"/>mmol/l, normal below 2.2) prompted skeletal muscle, liver and skin biopsies that revealed a multiple respiratory chain enzyme deficiency in muscle and liver homogenate and cultured skin fibroblasts (<ce:cross-ref refid="t0005" id="cf0325">Table 1</ce:cross-ref><ce:float-anchor refid="t0005"/>) <ce:cross-ref refid="bb0210" id="cf0330">[42]</ce:cross-ref>.</ce:para><ce:para id="p0070" view="all">He had a first episode of generalized tonic seizure aged 2<ce:hsp sp="0.25"/>years and his neurological condition rapidly worsened following an episode of acute fever (40<ce:hsp sp="0.25"/>Â°C) caused by a respiratory infection. At that age, he had severe denutrition, flat weight curve, no weight and height gain (-<ce:hsp sp="0.10"/>5 SD) and a mildly enlarged liver. Neurological examination revealed overt psychomotor retardation, severe trunk hypotonia, inability to sit and stand unaided and no speech. Intermittent horizontal nystagmus, with cerebellar ataxia and tremor were noted. He had a mild facial dysmorphism, with round face, epicanthic folds, arched palate, short neck, low-set ears and a unique bilateral median palmar crease. Brain MRI showed T1 hyposignal and T2 hypersignal of white matter and basal ganglia. Rapid aggravation of respiratory conditions required endotracheal intubation and assisted ventilation. Plasma lactates rose to 3.3-4.2<ce:hsp sp="0.25"/>mmol/l, he gradually developed abnormal limb movements then fell into a deep coma, and died following a cardiac arrest.</ce:para><ce:para id="p0075" view="all">During the next pregnancy, the mother expected dizygotic twin fetuses. A prenatal diagnosis based on assessment of respiratory chain enzyme activities in cultured skin fibroblasts on amniotic fluid was offered. Hemoglobin contamination of the samples rendered the very low respiratory chain activities; despite this the activity ratios clearly showed a severe complex IV deficiency in cells from the fetus twins leading to termination of the second pregnancy. The same test was normal in the third pregnancy and a normal baby girl was born, now 14<ce:hsp sp="0.25"/>years old (<ce:cross-ref refid="t0005" id="cf0335">Table 1</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0065" view="all"><ce:label>3.2</ce:label><ce:section-title id="st0085">Blue native-PAGE analysis</ce:section-title><ce:para id="p0080" view="all">Whilst skin fibroblasts were propagated for enzyme analysis it was clear that those from the subject harboring the mutation had a reduced doubling time on glucose medium compared to control lines (data available on request). Cell extracts were subsequently prepared and SDS-PAGE/western blot analysis revealed reduced steady-state level of COXII subunit, consistent with the decreased CIV activity (<ce:cross-ref refid="f0005" id="cf0340">Fig. 1</ce:cross-ref>A<ce:float-anchor refid="f0005"/>). Moreover, we also observed a decreased amount of nuclear encoded protein NDUFB8 (<ce:cross-ref refid="f0005" id="cf0345">Fig. 1</ce:cross-ref>A), which joins late in complex I assembly <ce:cross-ref refid="bb0220" id="cf0350">[44]</ce:cross-ref> and is consistent with the low CI activity in the biopsies. These decreases were consistent with the BN-PAGE data from fibroblast mitoplasts (<ce:cross-ref refid="f0005" id="cf0355">Fig. 1</ce:cross-ref>B, method as described <ce:cross-ref refid="bb0245" id="cf0360">[49]</ce:cross-ref>). Both complexes I and IV, detected by anti-GRIM19 antibody or mitochondrially-encoded COXI, were severely decreased in the subject, which in contrast exhibited control levels of complex II (70<ce:hsp sp="0.25"/>kDa SDHA subunit) and complex III (Core 2 subunit) (<ce:cross-ref refid="f0005" id="cf0365">Fig. 1</ce:cross-ref>B). No partial complexes were observed.</ce:para></ce:section><ce:section id="s0070" view="all"><ce:label>3.3</ce:label><ce:section-title id="st0090">Identifying the causative mutation by Microsatellite genotyping and mutation screening</ce:section-title><ce:para id="p0085" view="all">In order to identify the causative mutation a genome-wide search for homozygosity was undertaken using 382 polymorphic microsatellite markers (Genescan Linkage Mapping Set, version II (Perkin-Elmer). We obtained evidence for homozygosity in all affected individuals at loci D17S785, D17S784, and D17S928 on chromosome 17q24.2-q25.3 (<ce:cross-ref refid="f0010" id="cf0370">Fig. 2</ce:cross-ref>A<ce:float-anchor refid="f0010"/>). No other homozygous region was found with other markers. This 32.7<ce:hsp sp="0.25"/>cM region was then refined by additional microsatellite markers reducing the critical region to the 25<ce:hsp sp="0.25"/>cM interval, defined by loci D17S1352 and D17S928. This corresponds to a 8.4<ce:hsp sp="0.25"/>Mb physical region containing more than 170 genes, 10 of which encode mitochondrial proteins or proteins predicted to be mitochondrially targeted (<ce:italic>FDXR</ce:italic> (MIM <ce:inter-ref xlink:href="omim:103270" id="ir0365" xlink:type="simple">103270</ce:inter-ref>), <ce:italic>ICT1</ce:italic> (MIM <ce:inter-ref xlink:href="omim:603000" id="ir0370" xlink:type="simple">603000</ce:inter-ref>), <ce:italic>ATP5H</ce:italic> (MIM <ce:inter-ref xlink:href="omim:607196" id="ir0375" xlink:type="simple">607196</ce:inter-ref>), <ce:italic>MRPS7</ce:italic> (MIM <ce:inter-ref xlink:href="omim:611974" id="ir0380" xlink:type="simple">611974</ce:inter-ref>), <ce:italic>SLC25A19</ce:italic> (MIM <ce:inter-ref xlink:href="omim:606521" id="ir0385" xlink:type="simple">606521</ce:inter-ref>), <ce:italic>MRPL38</ce:italic> (MIM <ce:inter-ref xlink:href="omim:611844" id="ir0390" xlink:type="simple">611844</ce:inter-ref>), <ce:italic>PGS1</ce:italic> (<ce:inter-ref xlink:href="ncbi-n:NM_024419" id="ir0395" xlink:type="simple">NM_024419</ce:inter-ref>), <ce:italic>MRPL12</ce:italic> (MIM <ce:inter-ref xlink:href="omim:602375" id="ir0400" xlink:type="simple">602375</ce:inter-ref>), <ce:italic>SLC25A10</ce:italic> (MIM <ce:inter-ref xlink:href="omim:606794" id="ir0405" xlink:type="simple">606794</ce:inter-ref>), <ce:italic>FASN</ce:italic> (MIM <ce:inter-ref xlink:href="omim:600212" id="ir0410" xlink:type="simple">600212</ce:inter-ref>)). Considering the multiple RC deficiency observed in patient muscle, liver and fibroblasts and the abnormal BN-PAGE pattern reminiscent of translation deficiencies, we focused on genes involved in mitochondrial translation, excluding mutations in <ce:italic>MRPS7</ce:italic>, <ce:italic>MRPL38</ce:italic> and <ce:italic>ICT1</ce:italic> by direct sequencing.</ce:para><ce:para id="p0090" view="all">Sequencing of <ce:italic>MRPL12</ce:italic> exons and exon-intron boundaries on genomic DNA (primer sequences available on request) from the affected child identified a homozygous c.542C<ce:hsp sp="0.10"/>&gt;<ce:hsp sp="0.10"/>T transition in exon 5 (RefSeq accession number <ce:inter-ref xlink:href="ncbi-n:NM_002949.3" id="ir0415" xlink:type="simple">NM_002949.3</ce:inter-ref>, <ce:cross-ref refid="f0010" id="cf0375">Fig. 2</ce:cross-ref>B). This mutation changed a highly conserved alanine into a valine (p.Ala181Val, <ce:cross-ref refid="f0010" id="cf0380">Fig. 2</ce:cross-ref>C) and was predicted by Polyphen2 (<ce:inter-ref xlink:href="http://genetics.bwh.harvard.edu/pph2/" id="ir0420" xlink:type="simple">http://genetics.bwh.harvard.edu/pph2/</ce:inter-ref>) and SIFT (<ce:inter-ref xlink:href="http://sift.jcvi.org/" id="ir0425" xlink:type="simple">http://sift.jcvi.org/</ce:inter-ref>) software to be "probably damaging" and "deleterious" respectively. The parents were heterozygous for the mutation, both twin fetuses were homozygous and the healthy girl was wild-type homozygous. This mutation was absent from 100 controls of the same ethnic origin and from all SNP databases. Further, no additional <ce:italic>MRPL12</ce:italic> mutation could be identified in two other unrelated subjects with similar clinical presentation and biochemical defect.</ce:para><ce:para id="p0095" view="all">To demonstrate the deleterious nature of the p.Ala181Val MRPL12 substitution we used, overexpression of wild-type or mutant human <ce:italic>MRPL12</ce:italic> cDNA in the SV40-immortalized fibroblasts but rather recapitulating the respiratory phenotype of the patient fibroblasts, this was found to be lethal. Cells stopped growing, became polynucleated and progressively died.</ce:para></ce:section><ce:section id="s0075" view="all"><ce:label>3.4</ce:label><ce:section-title id="st0095">In silico analysis of the putative impact of A181V substitution</ce:section-title><ce:para id="p0100" view="all">Human MRPL12 is 27.5% identical in amino acid sequence to the previously crystallized <ce:italic>T. maritima</ce:italic> L12 ribosomal protein. The C-terminal domain (CTD) (107 to end in <ce:italic>Escherichia coli</ce:italic>) is conserved in evolution <ce:cross-ref refid="bb0250" id="cf0385">[50]</ce:cross-ref> and is required for initial binding and GTPase activation for both EF-Tu and EF-G. Indeed, both EF-Tu and EF-G have greatly diminished GTPase activity on ribosomes lacking the CTD of L12 <ce:cross-refs refid="bb0255 bb0260" id="cf0390">[51,52]</ce:cross-refs>. Superimposition of MRPL12 with the <ce:italic>Thermus thermophilus</ce:italic> 70S ribosome (PDB code: <ce:inter-ref xlink:href="pdb:2WRL" id="ir0430" xlink:type="simple">2WRL</ce:inter-ref>) lacking L7/L12 stalk proteins shows that MRPL12 Ala181 is located within this highly conserved region (<ce:cross-ref refid="f0015" id="cf0395">Fig. 3</ce:cross-ref>A<ce:float-anchor refid="f0015"/>). Moreover, modeling of MRPL12 shows Ala181 positioned in a helix potentially involved in translation factor interactions (<ce:cross-ref refid="f0015" id="cf0400">Fig. 3</ce:cross-ref>A/B). Bacterial L7/L12 CTDs also contain a number of strictly conserved residues that are involved in the initial contact with elongation factors <ce:cross-refs refid="bb0260 bb0265" id="cf0405">[52,53]</ce:cross-refs> and crucial for translation <ce:cross-ref refid="bb0270" id="cf0410">[54]</ce:cross-ref>. Alanine is one of the best helix forming residues and substitutions can therefore have profound energetic effects by perturbing packing interactions or tertiary contacts <ce:cross-ref refid="bb0275" id="cf0415">[55]</ce:cross-ref>. Thus, the p.Ala181Val change might be predicted to alter interactions with the elongation factors, and since MRPL7/12 bound to elongation factors is predicted to have a higher affinity for the ribosome <ce:cross-ref refid="bb0270" id="cf0420">[54]</ce:cross-ref>, the mutation may in turn affect both rate and accuracy of mitochondrial translation.</ce:para></ce:section><ce:section id="s0080" view="all"><ce:label>3.5</ce:label><ce:section-title id="st0100">Ribosome assembly</ce:section-title><ce:para id="p0105" view="all">The steady state level of MRPL12 in the subject's fibroblasts was reduced to 30% of control value (<ce:cross-ref refid="f0020" id="cf0425">Fig. 4</ce:cross-ref>A and B<ce:float-anchor refid="f0020"/>). The mt-LSU protein ICT1 was also decreased (~<ce:hsp sp="0.10"/>30% of control values) as was MRPL3 (by 37%) suggesting that a consequence of the MRPL12 mutation is a global defect in assembly of the large ribosomal subunit (mt-LSU). In order to estimate the effect of the MRPL12 mutation on assembly of the whole ribosome, we also tested three proteins of the small ribosomal subunit (SSU), MRPS18B, MRPS25 and DAP3. These were modestly decreased with levels of ~<ce:hsp sp="0.10"/>60-80% of control (<ce:cross-ref refid="f0020" id="cf0430">Fig. 4</ce:cross-ref>A and B). Correspondingly, 16S and 12S rRNA levels were decreased by 35% and 22% respectively (<ce:cross-ref refid="f0035" id="cf0435">Fig. 7</ce:cross-ref>A). Since porin indicated that there was no compensatory mitochondrial biogenesis and staining of the mitochondrial network with tetramethylrhodamine methyl ester showed no significant alteration in amount or distribution of mitochondria (AR and ZCL unpublished observation) we conclude that the <ce:italic>MRPL12</ce:italic> mutation destabilizes the protein resulting in less mt-LSU and to a lesser extent of the small subunit.</ce:para><ce:para id="p0110" view="all">In order to determine whether the MRPL12 mutation also induced changes in composition and assembly of the mitochondrial ribosomal large and small subunits, mitochondrial lysates from cultured fibroblasts (subject and control) were fractionated on isokinetic sucrose gradients (10-30%, as in Ref. <ce:cross-ref refid="bb0235" id="cf0440">[47]</ce:cross-ref>). If assembly of either the large subunit or the entire ribosome was affected then the distribution of individual ribosomal proteins would change within the gradient profile. On analysis MRPL12 from the patient was substantially decreased in all fractions but detectable in the fractions consistent with mt-LSU; however it was noticeably absent from the free pool (fractions 1 and 2, <ce:cross-ref refid="f0025" id="cf0445">Fig. 5</ce:cross-ref><ce:float-anchor refid="f0025"/>). This was in contrast to the control that exhibited a pool of free MRPL12, which has been reported to interact with POLRMT <ce:cross-ref refid="bb0280" id="cf0450">[56]</ce:cross-ref>. MRPL3 was also slightly reduced in subject cells but remained in fractions consistent with the large subunit. The MRPL12 mutation impacted more modestly on the small ribosomal subunit, with DAP3 apparently unaffected and MRPS18B found in lower amounts only in fractions 4 and 5 but otherwise with similar steady state levels and distribution profile compared to control. Since POLRMT and MRPL12 have been published as interactors, we analyzed both the steady state level and gradient distribution of POLRMT to see if these were affected by the MRPL12 mutation. Overall levels in the subject sample were decreased to 63% of control value (<ce:cross-ref refid="f0025" id="cf0455">Fig. 5</ce:cross-ref>B) but distribution in the gradient appeared largely unaffected with the exception of fraction 11, where levels were lower than control (<ce:cross-ref refid="f0025" id="cf0460">Fig. 5</ce:cross-ref>A bottom panels).</ce:para></ce:section><ce:section id="s0085" view="all"><ce:label>3.6</ce:label><ce:section-title id="st0105">In vitro translation</ce:section-title><ce:para id="p0115" view="all">To identify any effect on global mitochondrial protein synthesis, we studied <ce:italic>de novo</ce:italic> mitochondrial translation in cultured skin fibroblasts, as described in Ref. <ce:cross-ref refid="bb0225" id="cf0465">[45]</ce:cross-ref>. Although there was an overall decrease in mitochondrial translation compared to control, densitometric profiles showed that certain polypeptides were more affected than others (<ce:cross-ref refid="f0030" id="cf0470">Fig. 6</ce:cross-ref><ce:float-anchor refid="f0030"/>). In particular, there was a significant reduction of synthesis of COXI, COXII and COXIII subunits. Consistent with the respiratory chain activities, complex I polypeptides were affected to a lesser extent and cytochrome <ce:italic>b</ce:italic> from complex III appears to be spared. Despite the potential role of MRPL12 in translational accuracy, no aberrant translation product could be detected.</ce:para></ce:section><ce:section id="s0090" view="all"><ce:label>3.7</ce:label><ce:section-title id="st0110">Steady-state level of mitochondrial transcripts</ce:section-title><ce:para id="p0120" view="all">MRPL12 has been shown to interact with the mitochondrial RNA polymerase (POLRMT) and to stimulate mitochondrial transcription <ce:cross-refs refid="bb0280 bb0285" id="cf0475">[56,57]</ce:cross-refs>. Since the steady-state level of POLRMT in subject fibroblasts was modestly decreased, we analyzed the steady-state level of mitochondrial transcripts to see if these were similarly affected. Northern blots on control and subject fibroblast RNA did not show a decrease that paralleled the reduced levels of POLRMT. In fact there was a slight increase of <ce:italic>MTND1</ce:italic> in subject cells compared to control, whilst <ce:italic>MTCOI</ce:italic> and <ce:italic>MTCYB</ce:italic> transcripts appeared unaffected (<ce:cross-ref refid="f0035" id="cf0480">Fig. 7</ce:cross-ref>A<ce:float-anchor refid="f0035"/>). Conversely, as mentioned earlier, the levels of 16S and 12S rRNA were modestly decreased (<ce:cross-ref refid="f0035" id="cf0485">Fig. 7</ce:cross-ref>A) in a proportion that was consistent with the loss of MRPs with which they would associate. Analysis of the distribution on 10-30% (w/v) sucrose gradients (as in Ref. <ce:cross-ref refid="bb0310" id="cf0490">[58]</ce:cross-ref>) of two mt-mRNAs, <ce:italic>MTCOI</ce:italic> and <ce:italic>MTND1</ce:italic>, showed a relatively similar pattern for subject and control but in each case a smaller proportion of the subject transcript sedimented to the final fraction (data available on request). This was also true for the 16S and 12S rRNA. As no major redistribution in the sucrose gradient was observed, it is unlikely that the MRPL12 mutation causes a global defect in assembly of the mitoribosome.</ce:para><ce:para id="p0125" view="all">Since the levels of POLRMT were slightly decreased with normal or slightly elevated levels of mt-mRNA, we assessed the stability of transcripts to see if the half-lives were extended to compensate for reduced synthesis in order to maintain normal steady state levels. Mitochondrial transcription was poisoned by addition of low levels of ethidium bromide and RNA prepared at numerous time points thereafter (0-16<ce:hsp sp="0.25"/>h). Densitometry of the subsequent Northern demonstrated that half-lives of <ce:italic>MTCOI</ce:italic> and <ce:italic>MTND1</ce:italic> were extended, the latter more so, consistent with the modest increase in steady state levels (data available on request).</ce:para></ce:section><ce:section id="s0095" view="all"><ce:label>3.8</ce:label><ce:section-title id="st0115">MRPL12 dimerization and interaction with the mitoribosome</ce:section-title><ce:para id="p0130" view="all">MRPL12 is the orthologue of eubacterial L7/L12, where L7 is identical to L12 except that it is N-terminal acetylated. L7/L12 is also phosphorylated, which can affect both conformation and binding to partner ribosomal proteins (reviewed in Ref. <ce:cross-ref refid="bb0185" id="cf0495">[37]</ce:cross-ref>). This modification has now been confirmed to be present in mammalian MRPL12 <ce:cross-ref refid="bb0290" id="cf0500">[59]</ce:cross-ref>. In eubacteria, association of L7/12 to the large subunit takes place via the L10 protein such that two L7/L12 heterodimers normally associate per LSU <ce:cross-ref refid="bb0295" id="cf0505">[60]</ce:cross-ref>. Interestingly these dimers are actively exchanged on the 70S molecule without disruption of the ribosomal particle <ce:cross-refs refid="bb0270 bb0300" id="cf0510">[54,61]</ce:cross-refs>. The dimerization status and number of dimers attached to the human 55S has not been clarified. In order to identify if the stoichiometry of MRPL12 per mt-LSU was altered as a consequence of the mutation, we performed immunoprecipitation (IP) analysis on subject and control fibroblasts using antibodies to MRPL12. Analysis of the immunoprecipitate demonstrated similar levels small subunit polypeptides including DAP3 and MRPS18B in subject and control samples. In contrast, the total amount of MRPL12 was reduced (<ce:cross-ref refid="f0035" id="cf0515">Fig. 7</ce:cross-ref>B). In the patient the IP is restricted to MRPL12 in the large subunit or the fully assembled 55S with the total amount of MRPL12 being reduced as it lacks the "free" population. The densitometric measurements indicate that the patient IP has ~<ce:hsp sp="0.10"/>49% MRPL12 compared to control, in accordance with the gradient and steady state data. ICT1 appears to be sensitive to the MRPL12 levels and so is reduced in both the IP (~<ce:hsp sp="0.10"/>58% of control) and in the steady state westerns (<ce:cross-ref refid="f0020" id="cf0520">Fig. 4</ce:cross-ref>). The lower levels of MRPL12 could reflect loss of multimerization but since the region in the bacterial protein involved in multimerization is towards the N-terminus <ce:cross-ref refid="bb0305" id="cf0525">[62]</ce:cross-ref>, this mutation is unlikely to have an impact on dimer/multimer formation. The translation factor bound dimer has been suggested to have an increased affinity for the ribosome <ce:cross-refs refid="bb0270 bb0300" id="cf0530">[54,61]</ce:cross-refs>. Thus a possible explanation is that the mutation affects translation factor binding, thereby reducing the affinity of the mutant MRPL12 for the ribosome. If this were the case, however, then we would expect an increase in the pool of free MRPL12 whereas the subject exhibits a reduced pool of free MRPL12, which interacts with POLRMT <ce:cross-ref refid="bb0285" id="cf0535">[57]</ce:cross-ref>. The immunoprecipitation was performed using an MRPL12 specific antibody and so should contain all free MRPL12, MRPL12 associated with uncomplexed mt-LSU and MRPL12 as part of the fully assembled 55S. Since the levels of small and large subunit proteins appeared to be similar in subject and control, these data suggest that the mt-LSU and 55S assembly are unaffected by the mutation consistent with the gradient data for the protein and RNA components. Thus the reduced levels of mutant MRPL12 in this subject correspond to i) loss of stability, ii) a decrease in the free pool that is believed to interact with the mitochondrial RNA polymerase and iii) reduced translation potentially resulting from decreased interactions with translation factors, but with no detectable increase in aberrant translation products.</ce:para><ce:para id="p0135" view="all">In conclusion, we report a mutation in human <ce:italic>MRPL12</ce:italic> that results in growth retardation and neurological distress. It is interesting to note that whereas the eubacterial orthologue is not essential for in vitro translation assays, this <ce:italic>MRPL12</ce:italic> mutation induces a mitochondrial translation defect in human. This lack of predictability between orthologous proteins makes it important to examine and not assume what impact mutant forms or loss of MRPs may have on mitochondrial homeostasis and the resulting clinical manifestation. The data presented here provide another example, amongst a growing list of translation factors, which despite their apparent universal contribution to the synthesis of all mitochondrially encoded proteins, has a selective effect on the different oxidative phosphorylation complexes.</ce:para></ce:section></ce:section></ce:sections><ce:acknowledgment id="ac0005" view="all"><ce:section-title id="st0120">Acknowledgments</ce:section-title><ce:para id="p0140" view="all">This research was supported in part by the <ce:grant-sponsor id="gts0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Association FranÃ§aise contre les Myopathies</ce:grant-sponsor> (A.F.M.) and the <ce:grant-sponsor id="gts0010" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">French Agence Nationale pour la Recherche</ce:grant-sponsor> (A.N.R.). Z.M.A.C.-L. would like to thank <ce:grant-sponsor id="gts0015" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">The Wellcome Trust</ce:grant-sponsor> [<ce:grant-number refid="gts0015">096919/Z/11/Z</ce:grant-number>], and the <ce:grant-sponsor id="gts0020" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">BBSRC</ce:grant-sponsor> [<ce:grant-number refid="gts0020">BB/F011520/1</ce:grant-number>] for continuing support.</ce:para><ce:para id="p0145" view="all">We thank Alexander Tzagoloff for studies on ÎMRPL12 yeast strain.</ce:para></ce:acknowledgment></body><tail view="all"><ce:bibliography id="bi0005" view="all"><ce:section-title id="st0125">References</ce:section-title><ce:bibliography-sec id="bs0005" view="all"><ce:bib-reference id="bb0005"><ce:label>[1]</ce:label><sb:reference id="rf0005"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Anderson</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Sequence and organization of the human mitochondrial genome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>290</sb:volume-nr></sb:series><sb:date>1981</sb:date></sb:issue><sb:pages><sb:first-page>457</sb:first-page><sb:last-page>465</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0010"><ce:label>[2]</ce:label><sb:reference id="rf0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Zeviani</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Carelli</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mitochondrial disorders</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Opin. Neurol.</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>564</sb:first-page><sb:last-page>571</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0015"><ce:label>[3]</ce:label><sb:reference id="rf0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.P.</ce:given-name><ce:surname>Kemp</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Nuclear factors involved in mitochondrial translation cause a subgroup of combined respiratory chain deficiency</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain</sb:maintitle></sb:title><sb:volume-nr>134</sb:volume-nr></sb:series><sb:issue-nr>Pt 1</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>183</sb:first-page><sb:last-page>195</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0020"><ce:label>[4]</ce:label><sb:reference id="rf0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Calvo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Sci. Transl. Med.</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:issue-nr>118</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>118ra110</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0025"><ce:label>[5]</ce:label><sb:reference id="rf0025"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Galmiche</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Hum. Mutat.</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:issue-nr>11</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1225</sb:first-page><sb:last-page>1231</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0030"><ce:label>[6]</ce:label><sb:reference id="rf0030"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.C.</ce:given-name><ce:surname>Greaves</ce:surname></sb:author><sb:author><ce:given-name>A.K.</ce:given-name><ce:surname>Reeve</ce:surname></sb:author><sb:author><ce:given-name>R.W.</ce:given-name><ce:surname>Taylor</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Turnbull</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mitochondrial DNA and disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Pathol.</sb:maintitle></sb:title><sb:volume-nr>226</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>274</sb:first-page><sb:last-page>286</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0035"><ce:label>[7]</ce:label><sb:reference id="rf0035"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.G.</ce:given-name><ce:surname>Barth</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Valianpour</ce:surname></sb:author><sb:author><ce:given-name>V.M.</ce:given-name><ce:surname>Bowen</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Lam</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Duran</ce:surname></sb:author><sb:author><ce:given-name>F.M.</ce:given-name><ce:surname>Vaz</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>Wanders</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Med. Genet. A</sb:maintitle></sb:title><sb:volume-nr>126A</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>349</sb:first-page><sb:last-page>354</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0040"><ce:label>[8]</ce:label><sb:reference id="rf0040"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Valianpour</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>Wanders</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Overmars</ce:surname></sb:author><sb:author><ce:given-name>F.M.</ce:given-name><ce:surname>Vaz</ce:surname></sb:author><sb:author><ce:given-name>P.G.</ce:given-name><ce:surname>Barth</ce:surname></sb:author><sb:author><ce:given-name>A.H.</ce:given-name><ce:surname>van Gennip</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Linoleic acid supplementation of Barth syndrome fibroblasts restores cardiolipin levels: implications for treatment</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Lipid Res.</sb:maintitle></sb:title><sb:volume-nr>44</sb:volume-nr></sb:series><sb:issue-nr>3</sb:issue-nr><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>560</sb:first-page><sb:last-page>566</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0045"><ce:label>[9]</ce:label><sb:reference id="rf0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Ylikallio</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Suomalainen</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mechanisms of mitochondrial diseases</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Med.</sb:maintitle></sb:title><sb:volume-nr>44</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>41</sb:first-page><sb:last-page>59</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0050"><ce:label>[10]</ce:label><sb:reference id="rf0050"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Z.M.</ce:given-name><ce:surname>Chrzanowska-Lightowlers</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Horvath</ce:surname></sb:author><sb:author><ce:given-name>R.N.</ce:given-name><ce:surname>Lightowlers</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mitochondrial protein synthesis in health and disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Inherit. Metab. Dis.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>142</sb:first-page><sb:last-page>147</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0055"><ce:label>[11]</ce:label><sb:reference id="rf0055"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>McFarland</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Turnbull</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Batteries not included: diagnosis and management of mitochondrial disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Intern. Med.</sb:maintitle></sb:title><sb:volume-nr>265</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>210</sb:first-page><sb:last-page>228</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0060"><ce:label>[12]</ce:label><sb:reference id="rf0060"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.E.</ce:given-name><ce:surname>Christian</ce:surname></sb:author><sb:author><ce:given-name>L.L.</ce:given-name><ce:surname>Spremulli</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mechanism of protein biosynthesis in mammalian mitochondria</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochim. Biophys. Acta</sb:maintitle></sb:title><sb:volume-nr>1819</sb:volume-nr></sb:series><sb:issue-nr>9-10</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1035</sb:first-page><sb:last-page>1054</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0065"><ce:label>[13]</ce:label><sb:reference id="rf0065"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.W.</ce:given-name><ce:surname>Yarham</ce:surname></sb:author><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Elson</ce:surname></sb:author><sb:author><ce:given-name>E.L.</ce:given-name><ce:surname>Blakely</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>McFarland</ce:surname></sb:author><sb:author><ce:given-name>R.W.</ce:given-name><ce:surname>Taylor</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mitochondrial tRNA mutations and disease. Wiley interdisciplinary reviews</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>RNA</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>304</sb:first-page><sb:last-page>324</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0070"><ce:label>[14]</ce:label><sb:reference id="rf0070"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Rotig</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Human diseases with impaired mitochondrial protein synthesis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochim. Biophys. Acta</sb:maintitle></sb:title><sb:volume-nr>1807</sb:volume-nr></sb:series><sb:issue-nr>9</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1198</sb:first-page><sb:last-page>1205</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0075"><ce:label>[15]</ce:label><sb:reference id="rf0075"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Coenen</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N. Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>351</sb:volume-nr></sb:series><sb:issue-nr>20</sb:issue-nr><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>2080</sb:first-page><sb:last-page>2086</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0080"><ce:label>[16]</ce:label><sb:reference id="rf0080"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Antonicka</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Sasarman</ce:surname></sb:author><sb:author><ce:given-name>N.G.</ce:given-name><ce:surname>Kennaway</ce:surname></sb:author><sb:author><ce:given-name>E.A.</ce:given-name><ce:surname>Shoubridge</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The molecular basis for tissue specificity of the oxidative phosphorylation deficiencies in patients with mutations in the mitochondrial translation factor EFG1</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Hum. Mol. Genet.</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:issue-nr>11</sb:issue-nr><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>1835</sb:first-page><sb:last-page>1846</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0085"><ce:label>[17]</ce:label><sb:reference id="rf0085"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Smeitink</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>79</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>869</sb:first-page><sb:last-page>877</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0090"><ce:label>[18]</ce:label><sb:reference id="rf0090"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Valente</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>80</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>44</sb:first-page><sb:last-page>58</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0095"><ce:label>[19]</ce:label><sb:reference id="rf0095"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Edvardson</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Shaag</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Kolesnikova</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Gomori</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Tarassov</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Einbinder</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Saada</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Elpeleg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>81</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>857</sb:first-page><sb:last-page>862</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0100"><ce:label>[20]</ce:label><sb:reference id="rf0100"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.C.</ce:given-name><ce:surname>Scheper</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Genet.</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>534</sb:first-page><sb:last-page>539</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0105"><ce:label>[21]</ce:label><sb:reference id="rf0105"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.G.</ce:given-name><ce:surname>Riley</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia - MLASA syndrome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>87</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>52</sb:first-page><sb:last-page>59</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0110"><ce:label>[22]</ce:label><sb:reference id="rf0110"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Belostotsky</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>88</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>193</sb:first-page><sb:last-page>200</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0115"><ce:label>[23]</ce:label><sb:reference id="rf0115"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.B.</ce:given-name><ce:surname>Pierce</ce:surname></sb:author><sb:author><ce:given-name>K.M.</ce:given-name><ce:surname>Chisholm</ce:surname></sb:author><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Lynch</ce:surname></sb:author><sb:author><ce:given-name>M.K.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Walsh</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Opitz</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>R.E.</ce:given-name><ce:surname>Klevit</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>King</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>108</sb:volume-nr></sb:series><sb:issue-nr>16</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>6543</sb:first-page><sb:last-page>6548</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0120"><ce:label>[24]</ce:label><sb:reference id="rf0120"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Gotz</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Exome sequencing identifies mitochondrial alanyl-tRNA synthetase mutations in infantile mitochondrial cardiomyopathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>88</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>635</sb:first-page><sb:last-page>642</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0125"><ce:label>[25]</ce:label><sb:reference id="rf0125"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Bayat</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>PLoS Biol.</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:issue-nr>3</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>e1001288</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0130"><ce:label>[26]</ce:label><sb:reference id="rf0130"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Steenweg</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Leukoencephalopathy with thalamus and brainstem involvement and high lactate 'LTBL' caused by EARS2 mutations</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain</sb:maintitle></sb:title><sb:volume-nr>135</sb:volume-nr></sb:series><sb:issue-nr>Pt 5</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>1387</sb:first-page><sb:last-page>1394</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0135"><ce:label>[27]</ce:label><sb:reference id="rf0135"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Elo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Hum. Mol. Genet.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:issue-nr>20</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>4521</sb:first-page><sb:last-page>4529</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0140"><ce:label>[28]</ce:label><sb:reference id="rf0140"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Zeharia</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Fischel-Ghodsian</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Casas</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Bykhocskaya</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Tamari</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Lev</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Mimouni</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Lerman-Sagie</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mitochondrial myopathy, sideroblastic anemia, and lactic acidosis: an autosomal recessive syndrome in Persian Jews caused by a mutation in the PUS1 gene</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Child Neurol.</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>449</sb:first-page><sb:last-page>452</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0145"><ce:label>[29]</ce:label><sb:reference id="rf0145"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Zeharia</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Acute infantile liver failure due to mutations in the TRMU gene</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>85</sb:volume-nr></sb:series><sb:issue-nr>3</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>401</sb:first-page><sb:last-page>407</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0150"><ce:label>[30]</ce:label><sb:reference id="rf0150"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Lin</ce:surname></sb:author><sb:author><ce:given-name>M.X.</ce:given-name><ce:surname>Guan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Isolation and characterization of the putative nuclear modifier gene MTO1 involved in the pathogenesis of deafness-associated mitochondrial 12 S rRNA A1555G mutation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>277</sb:volume-nr></sb:series><sb:issue-nr>30</sb:issue-nr><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>27256</sb:first-page><sb:last-page>27264</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0155"><ce:label>[31]</ce:label><sb:reference id="rf0155"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Antonicka</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>87</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>115</sb:first-page><sb:last-page>122</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0160"><ce:label>[32]</ce:label><sb:reference id="rf0160"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Weraarpachai</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Genet.</sb:maintitle></sb:title><sb:volume-nr>41</sb:volume-nr></sb:series><sb:issue-nr>7</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>833</sb:first-page><sb:last-page>837</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0165"><ce:label>[33]</ce:label><sb:reference id="rf0165"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Xu</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Morin</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Mitchell</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Ackerley</ce:surname></sb:author><sb:author><ce:given-name>B.H.</ce:given-name><ce:surname>Robinson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The role of the LRPPRC (leucine-rich pentatricopeptide repeat cassette) gene in cytochrome oxidase assembly: mutation causes lowered levels of COX (cytochrome c oxidase) I and COX III mRNA</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochem. J.</sb:maintitle></sb:title><sb:volume-nr>382</sb:volume-nr></sb:series><sb:issue-nr>Pt 1</sb:issue-nr><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>331</sb:first-page><sb:last-page>336</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0170"><ce:label>[34]</ce:label><sb:reference id="rf0170"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Weraarpachai</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Sasarman</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Nishimura</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Antonicka</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Aure</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Rotig</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Lombes</ce:surname></sb:author><sb:author><ce:given-name>E.A.</ce:given-name><ce:surname>Shoubridge</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mutations in C12orf62, a factor that couples COX I synthesis with cytochrome c oxidase assembly, cause fatal neonatal lactic acidosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Hum. Genet.</sb:maintitle></sb:title><sb:volume-nr>90</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>142</sb:first-page><sb:last-page>151</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0175"><ce:label>[35]</ce:label><sb:reference id="rf0175"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Miller</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Saada</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Shaul</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Shabtai</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Ben-Shalom</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Shaag</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Hershkovitz</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Elpeleg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>56</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>734</sb:first-page><sb:last-page>738</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0180"><ce:label>[36]</ce:label><sb:reference id="rf0180"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Saada</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Shaag</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Arnon</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Dolfin</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Miller</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Fuchs-Telem</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Lombes</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Elpeleg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (MRPS22) mutation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Med. Genet.</sb:maintitle></sb:title><sb:volume-nr>44</sb:volume-nr></sb:series><sb:issue-nr>12</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>784</sb:first-page><sb:last-page>786</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0185"><ce:label>[37]</ce:label><sb:reference id="rf0185"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.C.</ce:given-name><ce:surname>Koc</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Emdadul Haque</ce:surname></sb:author><sb:author><ce:given-name>L.L.</ce:given-name><ce:surname>Spremulli</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Current Views of the Structure of the Mammalian Mitochondrial Ribosome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Isr. J. Chem.</sb:maintitle></sb:title><sb:volume-nr>50</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>45</sb:first-page><sb:last-page>59</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0190"><ce:label>[38]</ce:label><sb:reference id="rf0190"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.W.</ce:given-name><ce:surname>O'Brien</ce:surname></sb:author><sb:author><ce:given-name>N.D.</ce:given-name><ce:surname>Denslow</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Anders</ce:surname></sb:author><sb:author><ce:given-name>B.C.</ce:given-name><ce:surname>Courtney</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The translation system of mitochondrial polysomes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochim. Biophys. Acta</sb:maintitle></sb:title><sb:volume-nr>1050</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>174</sb:first-page><sb:last-page>178</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0195"><ce:label>[39]</ce:label><sb:reference id="rf0195"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Helgstrand</ce:surname></sb:author><sb:author><ce:given-name>C.S.</ce:given-name><ce:surname>Mandava</ce:surname></sb:author><sb:author><ce:given-name>F.A.</ce:given-name><ce:surname>Mulder</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Liljas</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Sanyal</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Akke</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The ribosomal stalk binds to translation factors IF2, EF-Tu, EF-G and RF3 via a conserved region of the L12 C-terminal domain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Mol. Biol.</sb:maintitle></sb:title><sb:volume-nr>365</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>468</sb:first-page><sb:last-page>479</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0200"><ce:label>[40]</ce:label><sb:reference id="rf0200"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Dey</ce:surname></sb:author><sb:author><ce:given-name>A.V.</ce:given-name><ce:surname>Oleinikov</ce:surname></sb:author><sb:author><ce:given-name>R.R.</ce:given-name><ce:surname>Traut</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The hinge region of <ce:italic>Escherichia coli</ce:italic> ribosomal protein L7/L12 is required for factor binding and GTP hydrolysis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochimie</sb:maintitle></sb:title><sb:volume-nr>77</sb:volume-nr></sb:series><sb:issue-nr>12</sb:issue-nr><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>925</sb:first-page><sb:last-page>930</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0205"><ce:label>[41]</ce:label><sb:reference id="rf0205"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Pettersson</ce:surname></sb:author><sb:author><ce:given-name>C.G.</ce:given-name><ce:surname>Kurland</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Ribosomal protein L7/L12 is required for optimal translation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>77</sb:volume-nr></sb:series><sb:issue-nr>7</sb:issue-nr><sb:date>1980</sb:date></sb:issue><sb:pages><sb:first-page>4007</sb:first-page><sb:last-page>4010</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0210"><ce:label>[42]</ce:label><sb:reference id="rf0210"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Rustin</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Chretien</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Bourgeron</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Gerard</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Rotig</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Saudubray</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Munnich</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Biochemical and molecular investigations in respiratory chain deficiencies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. Chim. Acta</sb:maintitle></sb:title><sb:volume-nr>228</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>35</sb:first-page><sb:last-page>51</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0215"><ce:label>[43]</ce:label><sb:reference id="rf0215"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Calvo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Systematic identification of human mitochondrial disease genes through integrative genomics</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Genet.</sb:maintitle></sb:title><sb:volume-nr>38</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>576</sb:first-page><sb:last-page>582</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0220"><ce:label>[44]</ce:label><sb:reference id="rf0220"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.O.</ce:given-name><ce:surname>Vogel</ce:surname></sb:author><sb:author><ce:given-name>C.E.</ce:given-name><ce:surname>Dieteren</ce:surname></sb:author><sb:author><ce:given-name>L.P.</ce:given-name><ce:surname>van den Heuvel</ce:surname></sb:author><sb:author><ce:given-name>P.H.</ce:given-name><ce:surname>Willems</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Smeitink</ce:surname></sb:author><sb:author><ce:given-name>W.J.</ce:given-name><ce:surname>Koopman</ce:surname></sb:author><sb:author><ce:given-name>L.G.</ce:given-name><ce:surname>Nijtmans</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Identification of mitochondrial complex I assembly intermediates by tracing tagged NDUFS3 demonstrates the entry point of mitochondrial subunits</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>282</sb:volume-nr></sb:series><sb:issue-nr>10</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>7582</sb:first-page><sb:last-page>7590</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0225"><ce:label>[45]</ce:label><sb:reference id="rf0225"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Chomyn</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>In vivo labeling and analysis of human mitochondrial translation products</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Methods Enzymol.</sb:maintitle></sb:title><sb:volume-nr>264</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>197</sb:first-page><sb:last-page>211</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0230"><ce:label>[46]</ce:label><sb:reference id="rf0230"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.R.</ce:given-name><ce:surname>Soleimanpour-Lichaei</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>mtRF1a is a human mitochondrial translation release factor decoding the major termination codons UAA and UAG</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Molecular cell</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>745</sb:first-page><sb:last-page>757</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0235"><ce:label>[47]</ce:label><sb:reference id="rf0235"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Richter</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Rorbach</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Pajak</ce:surname></sb:author><sb:author><ce:given-name>P.M.</ce:given-name><ce:surname>Smith</ce:surname></sb:author><sb:author><ce:given-name>H.J.</ce:given-name><ce:surname>Wessels</ce:surname></sb:author><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Huynen</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Smeitink</ce:surname></sb:author><sb:author><ce:given-name>R.N.</ce:given-name><ce:surname>Lightowlers</ce:surname></sb:author><sb:author><ce:given-name>Z.M.</ce:given-name><ce:surname>Chrzanowska-Lightowlers</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human mitochondrial ribosome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>EMBO J.</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>1116</sb:first-page><sb:last-page>1125</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0240"><ce:label>[48]</ce:label><sb:reference id="rf0240"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Z.M.</ce:given-name><ce:surname>Chrzanowska-Lightowlers</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Preiss</ce:surname></sb:author><sb:author><ce:given-name>R.N.</ce:given-name><ce:surname>Lightowlers</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Inhibition of mitochondrial protein synthesis promotes increased stability of nuclear-encoded respiratory gene transcripts</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>269</sb:volume-nr></sb:series><sb:issue-nr>44</sb:issue-nr><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>27322</sb:first-page><sb:last-page>27328</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0245"><ce:label>[49]</ce:label><sb:reference id="rf0245"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.G.J.</ce:given-name><ce:surname>Nijtmans</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Henderson</ce:surname></sb:author><sb:author><ce:given-name>I.J.</ce:given-name><ce:surname>Holt</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Blue native electrophoresis to study mitochondrial and other protein complexes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Methods</sb:maintitle></sb:title><sb:volume-nr>26</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>327</sb:first-page><sb:last-page>334</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0250"><ce:label>[50]</ce:label><sb:reference id="rf0250"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Hemmerich</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>von Mikecz</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Neumann</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Sozeri</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Wolff-Vorbeck</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Zoebelein</ce:surname></sb:author><sb:author><ce:given-name>U.</ce:given-name><ce:surname>Krawinkel</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Structural and functional properties of ribosomal protein L7 from humans and rodents</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nucleic Acids Res.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>1993</sb:date></sb:issue><sb:pages><sb:first-page>223</sb:first-page><sb:last-page>231</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0255"><ce:label>[51]</ce:label><sb:reference id="rf0255"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Mohr</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Wintermeyer</ce:surname></sb:author><sb:author><ce:given-name>M.V.</ce:given-name><ce:surname>Rodnina</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>GTPase activation of elongation factors Tu and G on the ribosome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochemistry</sb:maintitle></sb:title><sb:volume-nr>41</sb:volume-nr></sb:series><sb:issue-nr>41</sb:issue-nr><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>12520</sb:first-page><sb:last-page>12528</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0260"><ce:label>[52]</ce:label><sb:reference id="rf0260"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Diaconu</ce:surname></sb:author><sb:author><ce:given-name>U.</ce:given-name><ce:surname>Kothe</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Schlunzen</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Fischer</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Harms</ce:surname></sb:author><sb:author><ce:given-name>A.G.</ce:given-name><ce:surname>Tonevitsky</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Stark</ce:surname></sb:author><sb:author><ce:given-name>M.V.</ce:given-name><ce:surname>Rodnina</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Wahl</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Structural basis for the function of the ribosomal L7/12 stalk in factor binding and GTPase activation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>121</sb:volume-nr></sb:series><sb:issue-nr>7</sb:issue-nr><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>991</sb:first-page><sb:last-page>1004</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0265"><ce:label>[53]</ce:label><sb:reference id="rf0265"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Nechifor</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Murataliev</ce:surname></sb:author><sb:author><ce:given-name>K.S.</ce:given-name><ce:surname>Wilson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Functional interactions between the G' subdomain of bacterial translation factor EF-G and ribosomal protein L7/L12</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>282</sb:volume-nr></sb:series><sb:issue-nr>51</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>36998</sb:first-page><sb:last-page>37005</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0270"><ce:label>[54]</ce:label><sb:reference id="rf0270"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.K.</ce:given-name><ce:surname>Kopke</ce:surname></sb:author><sb:author><ce:given-name>P.A.</ce:given-name><ce:surname>Leggatt</ce:surname></sb:author><sb:author><ce:given-name>A.T.</ce:given-name><ce:surname>Matheson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Structure function relationships in the ribosomal stalk proteins of archaebacteria</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>267</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>1992</sb:date></sb:issue><sb:pages><sb:first-page>1382</sb:first-page><sb:last-page>1390</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0275"><ce:label>[55]</ce:label><sb:reference id="rf0275"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.M.</ce:given-name><ce:surname>Gregoret</ce:surname></sb:author><sb:author><ce:given-name>R.T.</ce:given-name><ce:surname>Sauer</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tolerance of a protein helix to multiple alanine and valine substitutions</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Fold. Des.</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>119</sb:first-page><sb:last-page>126</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0280"><ce:label>[56]</ce:label><sb:reference id="rf0280"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Cotney</ce:surname></sb:author><sb:author><ce:given-name>G.S.</ce:given-name><ce:surname>Shadel</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Human mitochondrial ribosomal protein MRPL12 interacts directly with mitochondrial RNA polymerase to modulate mitochondrial gene expression</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>282</sb:volume-nr></sb:series><sb:issue-nr>17</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>12610</sb:first-page><sb:last-page>12618</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0285"><ce:label>[57]</ce:label><sb:reference id="rf0285"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.V.</ce:given-name><ce:surname>Surovtseva</ce:surname></sb:author><sb:author><ce:given-name>T.E.</ce:given-name><ce:surname>Shutt</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Cotney</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Cimen</ce:surname></sb:author><sb:author><ce:given-name>S.Y.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>E.C.</ce:given-name><ce:surname>Koc</ce:surname></sb:author><sb:author><ce:given-name>G.S.</ce:given-name><ce:surname>Shadel</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mitochondrial ribosomal protein L12 selectively associates with human mitochondrial RNA polymerase to activate transcription</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>108</sb:volume-nr></sb:series><sb:issue-nr>44</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>17921</sb:first-page><sb:last-page>17926</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0310"><ce:label>[58]</ce:label><sb:reference id="rf0310"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Dennerlein</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Rozanska</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Wydro</ce:surname></sb:author><sb:author><ce:given-name>Z.M.</ce:given-name><ce:surname>Chrzanowska-Lightowlers</ce:surname></sb:author><sb:author><ce:given-name>R.N.</ce:given-name><ce:surname>Lightowlers</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Human ERAL1 is a mitochondrial RNA chaperone involved in the assembly of the 28S small mitochondrial ribosomal subunit</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>The Biochem. J.</sb:maintitle></sb:title><sb:volume-nr>430</sb:volume-nr></sb:series><sb:issue-nr>3</sb:issue-nr><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>551</sb:first-page><sb:last-page>558</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0290"><ce:label>[59]</ce:label><sb:reference id="rf0290"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.C.</ce:given-name><ce:surname>Koc</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Koc</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Regulation of mammalian mitochondrial translation by post-translational modifications</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochim. Biophys. Acta</sb:maintitle></sb:title><sb:volume-nr>1819</sb:volume-nr></sb:series><sb:issue-nr>9-10</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>1055</sb:first-page><sb:last-page>1066</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0295"><ce:label>[60]</ce:label><sb:reference id="rf0295"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.V.</ce:given-name><ce:surname>Bocharov</ce:surname></sb:author><sb:author><ce:given-name>A.T.</ce:given-name><ce:surname>Gudkov</ce:surname></sb:author><sb:author><ce:given-name>E.V.</ce:given-name><ce:surname>Budovskaya</ce:surname></sb:author><sb:author><ce:given-name>A.S.</ce:given-name><ce:surname>Arseniev</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Conformational independence of N- and C-domains in ribosomal protein L7/L12 and in the complex with protein L10</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>FEBS Lett.</sb:maintitle></sb:title><sb:volume-nr>423</sb:volume-nr></sb:series><sb:issue-nr>3</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>347</sb:first-page><sb:last-page>350</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0300"><ce:label>[61]</ce:label><sb:reference id="rf0300"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Deroo</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Hyung</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Marcoux</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Gordiyenko</ce:surname></sb:author><sb:author><ce:given-name>R.K.</ce:given-name><ce:surname>Koripella</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Sanyal</ce:surname></sb:author><sb:author><ce:given-name>C.V.</ce:given-name><ce:surname>Robinson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mechanism and rates of exchange of L7/L12 between ribosomes and the effects of binding EF-G</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>ACS Chem. Biol.</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>1120</sb:first-page><sb:last-page>1127</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0305"><ce:label>[62]</ce:label><sb:reference id="rf0305"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.V.</ce:given-name><ce:surname>Oleinikov</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Perroud</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>R.R.</ce:given-name><ce:surname>Traut</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Structural and functional domains of <ce:italic>Escherichia coli</ce:italic> ribosomal protein L7/L12. The hinge region is required for activity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>268</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>1993</sb:date></sb:issue><sb:pages><sb:first-page>917</sb:first-page><sb:last-page>922</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc>
